

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092405 A2

(51) International Patent Classification⁷: C12Q 1/68

George [GR/GR]; 1st Dept of Internal Medicine, National and Kapodistrian University of Athens, 6 Chr. Lada str., GR-10561 Athens (GR).

(21) International Application Number:
PCT/CA2004/000522

(74) Agent: MBM & CO.; P.O. Box 809, Station B, Ottawa, Ontario K1P 5P9 (CA).

(22) International Filing Date: 8 April 2004 (08.04.2004)

(25) Filing Language: English

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
60/462,867 15 April 2003 (15.04.2003) US
60/488,607 18 July 2003 (18.07.2003) US
60/498,458 28 August 2003 (28.08.2003) US

(71) Applicant (for all designated States except US): XENON GENETICS INC. [CA/CA]; 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SAMUELS, Mark, E. [US/CA]; 2743 West 37th Ave., Vancouver, British Columbia V6N 2T5 (CA). LUDWIG, Erwin, H. [CA/US]; 48 El Cerrito, San Anselmo, CA 94960 (US). MACDONALD, Marcla, L.E. [CA/CA]; 102-1345 West 13th Ave., Vancouver, British Columbia V6H 1N7 (CA). FRANCHINI, Patrick [CA/CA]; 49-7345 Sandborne Ave., Burnaby, British Columbia V3N 4W6 (CA). GOLDBERG, Yigal, Paul [CA/CA]; 62 West 18th Avenue, Vancouver, British Columbia V5Y 2A4 (CA). KAMBOJ, Rajender, K. [CA/CA]; 5809 Sperling Avenue, Burnaby, British Columbia V5E 2T6 (CA). PAPANIKOLAOU,

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: JUVENILE HEMOCHROMATOSIS GENE (HFE2A), EXPRESSION PRODUCTS AND USES THEREOF

(57) Abstract: Polynucleotide and polypeptide sequences for HFE2A, as well as mutations associated with juvenile hemochromatosis, and methods of utilizing these for the screening and identification of agents for the treatment of diseases of iron metabolism, including small organic compounds, are disclosed along with methods of treating and/or ameliorating diseases of iron metabolism, especially in human patients are disclosed. Diagnostic compounds, kits and methods using HFE2A are also described.

WO 2004/092405 A2

17 / PRTS

10/552158
JC09 Rec'd PCT/PTO 12 OCT 2005

WO 2004/092405

PCT/CA2004/000522

JUVENILE HEMOCHROMATOSIS GENE (HFE2A), EXPRESSION PRODUCTS AND USES THEREOF

1. This patent application claims priority of US provisional applications Serial No. 60/462,867, filed 15 April 2003, Serial No. US/60/488,607, filed 18 July 2003, and Serial No. 60/498,458, filed 28 August 2003, the disclosures of which are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

The present invention relates generally to the field of iron metabolism diseases, especially juvenile hemochromatosis, to a gene associated therewith, and to methods of using this gene, including expression products thereof, for the screening and identification of agents useful in the treatment of diseases of iron metabolism, including methods of such treatment.

BACKGROUND OF THE INVENTION

At least 4 iron-overload disorders labeled hemochromatosis have been identified on the basis of clinical, biochemical, and genetic characteristics. Hemochromatosis type 1 is classic hemochromatosis (sometimes designated "HFE") (see OMIM Number: 235200; Online Mendelian Inheritance in Man, OMIM™. Johns Hopkins University, Baltimore, MD, at www.ncbi.nlm.nih.gov/omim/), an autosomal recessive disorder, which is caused by mutation in a gene designated HFE on chromosome 6p21.3. The medical disorder called juvenile hemochromatosis (sometimes called "JH" or "juvenile haemochromatosis"), is also known as hemochromatosis type 2 ("HFE2"). Hemochromatosis type 3 (HFE3; OMIM 604250), an autosomal

recessive disorder, is caused by mutation in the gene encoding transferrin receptor-2 (TFR2; OMIM 604720), which maps to 7q22. Hemochromatosis type 4 (HFE4; OMIM 606069), an autosomal dominant disorder, is caused by mutation in the SLC11A3 gene (OMIM 604653), which encodes ferroportin and maps to 2q32.

5 In some families juvenile hemochromatosis shows linkage to chromosome 1q21, whereas in others it is caused by mutation in the gene encoding hepcidin antimicrobial peptide, which maps to chromosome 19q13. The two forms of juvenile hemochromatosis (HFE2) are tentatively designated HFE2A and HFE2B, respectively. The present invention relates to the genetic basis of HFE2A, the form of JH linked to chromosome 1q21.

Juvenile hemochromatosis (JH) differs from typical hereditary hemochromatosis. While HFE has a prevalent male expression, JH affects both sexes equally. JH involves iron accumulation, which begins early in life and typically causes clinical symptoms before the age of 30 years. JH is a more severe disease than typical hereditary hemochromatosis, with JH showing hypogonadotropic hypogonadism, heart failure, arrhythmias and/or cardiomyopathy as frequent features. If untreated, the disease is lethal because of cardiac and other complications.

15 Identification of 1q21 as the chromosomal location of HFE2A was first reported in Roetto et al., *Am. J. Hum. Genet.* 64:1388-1393 (1999) but this locus did not correspond to the chromosomal location of any known gene involved in iron metabolism.

The present invention provides identification of the hereditary basis for HFE2A, thereby facilitating development of more potent agents for treating diseases of iron metabolism. Administration of the HFE2A gene or protein itself may be therapeutic. Alternatively, the underlying genetic mutation identifies a novel therapeutic target for treating diseases of iron metabolism. This therapeutic target can be used to identify and discover more effective therapeutic agents. Diagnostic compounds, kits and methods using HFE2A are also included which may be used to diagnose JH as well as to diagnose

and predict onset and severity of adult hemochromatosis and to distinguish between types of iron metabolism disorders.

BRIEF SUMMARY OF THE INVENTION

5 The invention relates to the discovery that juvenile hemochromatosis (hemochromatosis type 2A, or HFE2A), is caused by a mutation in a human gene found at 1q22 having the nucleotide sequence as set out in SEQ ID Nos. 1 – 9, and/or the corresponding amino acid sequences as set out in SEQ ID Nos. 10-12. The gene and the protein are referred to herein as HFE2A
10 and also as hemojuvelin, these words referring the gene, the gene product and the protein expressed therefrom, unless the context specifies otherwise. The gene has also been named HFE2, by which is meant the form JH caused by the gene at 1q21. This naming protocol is not essential to the invention claimed herein.

15 In one aspect, the present invention relates to a method for identifying an agent that modulates hemojuvelin, comprising contacting a test compound with hemojuvelin and determining a change in hemojuvelin activity due to the compound, thereby identifying a modulator of the type being sought. The modulator may be a drug-like small molecule, an antibody, an antisense
20 nucleic acid, a ribozyme or any other compound which changes the activity of the gene or protein.

 In one aspect, the present invention relates to method for identifying an agent that modulates HFE2A gene expression, comprising contacting a test compound with a polynucleotide comprising a HFE2A gene and under
25 conditions promoting expression of said gene (i.e., conditions wherein the polynucleotide is being expressed) and determining a change in expression due to the presence of the test compound. This identifies the test compound as such a modulator. In a preferred embodiment, this change in expression is detected as a change in transcription of the gene, preferably where the gene
30 is a mammalian gene and most preferably where the gene is expressed by a cell.

In another aspect, the present invention relates to a method for identifying an agent that modulates HFE2A gene expression, comprising contacting a test compound with a reporter gene operably linked to a promoter sequence and determining a change in expression of the reporter gene due to the test compound, thus identifying a modulator of the construct. Preferably, this is modulation of transcription of said reporter gene operably linked to an HFE2A promoter, most preferably a mammalian HFE2A, such as a mouse, rat or human HFE2A promoter.

In a further aspect, the present invention relates to a method for treating and/or preventing a disorder in an animal comprising administering to an animal afflicted therewith, or at risk of developing said disorder, a therapeutically effective amount of an HFE2A modulator. In a preferred embodiment, the HFE2A modulator exhibits modulating activity in a method of the invention, most preferably wherein said agent was first identified as an HFE2A modulator using said method and was not otherwise known to have such activity.

In a yet further aspect, the present invention relates to a method to diagnose individuals afflicted with or at risk of developing HFE2A or a related disorder comprising determining the nucleic acid sequence of the HFE2A gene in said individual wherein a mutation or polymorphism of said gene identifies said individual as an individual afflicted with or at risk of developing HFE2A or a related disorder.

The present invention also contemplates a method for identifying a compound capable of modulating a HFE2A activity, comprising: (a) contacting a cell which expresses HFE2A with a test compound; and (b) assaying the ability of the test compound to modulate the transcription of a HFE2A nucleic acid or the activity of HFE2A polypeptide, thereby identifying a compound capable of modulating a HFE2A activity. In a preferred embodiment of such method, the compound is an anti-HFE2A polypeptide antibody, a ribozyme or is an antisense HFE2A nucleic acid molecule. In one preferred embodiment thereof, the compound is a HFE2A ribozyme.

The present invention also encompasses an isolated polynucleotide or isolated polypeptide of the genes disclosed herein.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 is a schematic of LOC148738 Gene structure. The LOC148738 Gene has four exons and five transcripts. The five transcripts code for 3 proteins of 200 AA, 313 AA and 426 AA. Exon 2 was predicted by Ensembl from cDNA sequence AK098165.1. The acceptor site for Exon 2 is inferred from the genomic sequence. Exons 3a and 3b have the same
10 acceptor site but different donor sites. Untranslated sequence is white, translated sequence is black. The transcripts are listed from longest to shortest.

Figure 2 is an alignment of the human, mouse and rat promoter sequences for HFE2A. The transcriptional start site of the human sequence
15 begins at position 1514 of this alignment and exon 1 ends at position 1676. Three repetitive sequences are present within the human sequence, a (TAGA)_n at position 58 to 129, an alu repetitive element at position 324 to 603 and a (GGAA)_n at position 604 to 702. These sequences are not present in the rodent sequences and possibly define the promoter boundary for the
20 gene. Sequence homology between species is lost 5' of position 844 of this alignment, about 670 bp 5' of the transcriptional start. A putative transcriptional initiation site (TATA) is conserved in all three species, at 27 to 24 bp 5' of the transcriptional start in the human.

Figure 3 shows a Protein Sequence Alignment of Human LOC148738
25 426 aa Gene Product (Protein3) and human paralogs; Human Repulsive Guidance Molecule (Human RGM) (NCBI: NP_064596.1) on Chromosome 15 and ENSESTP00000023393 (Ensembl) identified on Chromosome 5.— Comparison of human paralogs

Figure 4 shows a Sequence Alignment of LOC148738 sequences
30 using clustalx. Human (Protein3), Mouse (Ensembl: ENSMUSESTP00000016634), Rat (Translated from NCBI: AK098165.1 Though annotated as human sequence it is 99.9% identical to Rat genomic

sequence and only 86.6% identical to human genomic sequence) and Fugu (Ensembl: SINFRUP00000138308).

Figure 5 shows a Protein Sequence Alignment of Human LOC148738 gene product and Chicken Repulsive Guidance Molecule (RGM). Human (Protein3), Chicken_RGM (Translation of NCBI: AY128507.1). A = Signal Peptide, B = RGD, C = N-Glycosylation site, D = Partial von Willebrand Type D Domain, E = GPI modification, Arrow = Possible cleavage site.

Figure 6A shows a summary of high degree of similarity between homologs of several species.

Figure 6B shows the high degree of similarity between genes similar to HFE2A in different species.

Fig 7(a) – Structural features in the 426 aa translated open reading frame of LOC148738. RGD – cell attachment tri amino acid motif, vWF – Partial von Willebrand factor type D domain and TM – Transmembrane domain. The arrows mark a possible proteolytic site between positions 172 and 173, a furin cleavage site between positions 335 and 336 and a predicted GPI modification site at position 400. Fig. 7(b) shows the prediction of signal peptide cleavage site in 426 aa translation of HFE2A using SignalP (Henrik Nielsen et al. *Protein Engineering*, 10, 1-6 (1997)). Peptide cleavage site is predicted to be between S35 and Q36. Figure 7(c) shows the prediction of transmembrane regions in 426 aa translation of HFE2A using TMHMM. The transmembrane region is from residues 403-425. Figure 7(d) shows the identification of partial von Willebrand Type D domain (57%) using NCBI Conserved Domain Search. (LOC148738 = HFE2A); Figure 7(e) shows Possible proteolytic cleavage site (arrow) between residues 172D and 173P identified by sequence comparison with Chicken Repulsive Guidance Molecule (RGM).

Figure 8 shows Nucleic acid and amino-acid sequence of 426 aa open-reading frame translated from Transcript4 of LOC148738 (Protein3). This protein is identical to the Ensembl protein ENSP00000304614 from the predicted Ensembl transcript ENST00000306561. **Box**, initiating codon; **triangle**, potential signal peptide cleavage site; **dots**, RGD site; **cross**,

predicted O-glycosylation sites (NetOGlyc2.0 predicted); **diamonds**, predicted N-glycosylation sites (NetNGlyc 1.0 predicted); **arrow**, putative cleavage site from comparison with chicken RGM; **double arrow**, furin cleavage site; **square**, predicted GPI anchor modification site; **asterisk**, stop codon.

- 5 Fig 9 (a) – (e) – shows family pedigrees used to identify genetic mutation causing juvenile hemochromatosis.

DETAILED DESCRIPTION OF THE INVENTION

10 The present invention provides a gene and its corresponding protein related to diseases of iron metabolism, referred to as hemojuvelin or HFE2A. Hemojuvelin and HFE2A refers to both the gene, the gene product and the protein expressed therefrom, unless the context specifies otherwise.

15 In accordance with the present invention, the human HFE2A gene is disclosed. This gene, when mutated, results in juvenile hemochromatosis (hemochromatosis type 2A). The gene has also been named HFE2, by which is meant the form JH caused by the gene at 1q21. The gene product/protein is also sometimes called "hemojuvelin." This naming protocol is not essential to the invention claimed herein.

20 In one aspect, the invention relates to the nucleic acid sequence for HFE2A, including the genomic sequence, mRNA or cDNA, polymorphic, allelic, isoforms (adult, neo-natal, etc.) and mutant forms thereof, and nucleic acid constructs of the gene, including vectors, plasmids and recombinant cells and transgenic organisms containing or corresponding to HFE2A (or knock-outs thereof). Such nucleic acid sequences are set forth in SEQ. ID NOS. 1 –
25 9, and 13 - 22.

30 In another aspect, the invention relates to the gene product of HFE2A, sometimes called herein hemojuvelin or HFE2A polypeptide, including the polypeptide, protein, and amino acid sequence, and the polymorphic, allelic, isoforms (adult, neo-natal, etc.) and mutant forms thereof, mRNA or other transcripts of HFE2A, and recombinant cells and transgenic organisms wherein this polypeptide or a polypeptide corresponding thereto is expressed.

Such amino acid sequences are set forth in SEQ. ID NOs: 10 - 12 and 23 - 28.

In one aspect of the present invention, HFE2A is incorporated into a screening assay whereby compounds (potential therapeutic agents) are tested to determine if they modulate HFE2A gene expression activity, thereby identifying potential therapeutic agents.

In accordance with the foregoing, the present invention relates to method for identifying an agent that modulates HFE2A gene expression, comprising:

- a) contacting a test compound with a cell expressing an HFE2A gene;
- b) determining a change in expression of said HFE2A gene as a result of said contacting,

wherein a change in expression identifies said test compound as an agent that modulates HFE2A gene expression.

In a preferred embodiment, this change in expression is detected by detecting a change in transcription of said gene, such as where there is a decrease or increase in transcription. In another preferred embodiment, the HFE2A gene is a mammalian HFE2A gene, most preferably where the mammal is a mouse, rat or human.

In another preferred embodiment, the gene whose modulation is to be determined is present in a mammalian cell, preferably a recombinant cell, including where the cell is a macrophage, inflammatory cell, liver cell, hepatocyte, intestinal cell, hematopoietic cell, pancreatic cell, skeletal muscle cell or a cell of the nervous system.

In another aspect, the present invention relates to a method for identifying an agent that modulates the activity of an HFE2A polypeptide, comprising:

- a) contacting a test compound with an HFE2A polypeptide and under conditions supporting an activity of said polypeptide; and
- b) determining a change in said activity of said polypeptide as a result of said contacting,

wherein a change in the activity identifies said test compound as an agent that modulates the activity of an HFE2A polypeptide.

In preferred embodiments of such methods, the HFE2A-encoded polypeptide is a mammalian HFE2A polypeptide, most preferably from mouse, rat or human.

In other preferred embodiments, the modulation is a decrease or increase in said biological activity. In a highly useful embodiment, the polypeptide is in, or is part of, a cell, preferably a mammalian cell, most preferably a recombinant cell, including where the cell is a macrophage, inflammatory cell, liver cell, hepatocyte, intestinal cell, hematopoietic cell, pancreatic cell, skeletal muscle cell or a cell of the nervous system. In other preferred embodiments, the cell has been engineered to contain said polypeptide, such as by genetic engineering, especially where said cell does not express said polypeptide absent said engineering.

In an additional preferred embodiment, the polypeptide is encoded by a polynucleotide having the sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 and 9, most preferably wherein said polypeptide comprises an amino acid sequence selected from the sequence of SEQ ID NO: 10, 11 and 12.

The present invention also relates to a cell line comprising a one or more of said polynucleotides of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 and 9, including recombinant forms of the polynucleotides, as well as a cell line comprising one or more of the polypeptides of SEQ ID NO: 10, 11 and 12, preferably a recombinant form of the polypeptide. In another embodiment, the present invention relates to use of such a cell line in a method for identifying compositions which modulate expression or activity of hemojuvelin.

In a further aspect, the present invention relates to a method for treating and/or preventing a disorder in an animal comprising administering to an animal afflicted therewith, or at risk of developing said disorder, a therapeutically effective amount of an HFE2A modulator. In a preferred embodiment, the HFE2A modulator exhibits modulating activity in a method of the invention, most preferably wherein said agent was first identified as an

HFE2A modulator using said method and was not otherwise known to have such activity. In a preferred embodiment of such method, the HFE2A modulator is a selective HFE2A agonist, or a selective HFE2A antagonist, including pharmaceutically acceptable salts thereof, and/or any combinations of these, including where these are in a pharmaceutically acceptable carrier. In an embodiment, said disorder is a disease of iron metabolism, including an iron overload disorder and/or an iron deficiency disorder. Such disease of iron metabolism may also include one or more of Type I diabetes, Type II diabetes and insulin resistance.

10 In a yet further aspect, the present invention relates to a method to diagnose individuals afflicted with or at risk of developing HFE2A or a related disorder comprising determining all or part of the nucleic acid sequence of the HFE2A gene in said individual wherein a mutation or polymorphism of said gene identifies said individual as an individual afflicted with or at risk of developing HFE2A or a related disorder. In another such embodiment, the present invention relates to a method to diagnose individuals affected by or at risk of developing HFE2A or a related disorder comprising determining all or part of the amino acid sequence of HFE2A polypeptide in said individual wherein a mutation or polymorphism of said gene identifies said individual as an individual affected by or at risk of developing HFE2A or a related disorder.

20 The present invention also contemplates a method for identifying a compound capable of modulating a HFE2A activity, comprising: (a) contacting a cell which expresses HFE2A with a test compound; and (b) assaying the ability of the test compound to modulate the transcription of a HFE2A nucleic acid or the activity of HFE2A Polypeptide, thereby identifying a compound capable of modulating a HFE2A activity. In a preferred embodiment of such method, the compound is an anti-HFE2A polypeptide antibody, a ribozyme or is an antisense HFE2A nucleic acid molecule. In one preferred embodiment thereof, the compound is a HFE2A ribozyme. In another embodiment, the compound is a small organic molecule.

The present invention also encompasses an isolated polynucleotide comprising a polynucleotide having a nucleotide sequence with at least 60 percent identity to a sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 19, 20, 21 and 22. In other embodiments thereof, said percent identity is at least 70 percent, more preferably at least 78 percent, even more preferably at least 90 percent, yet more preferably at least 95 percent, still more preferably at least 98 percent, and most preferably where the nucleotide sequence is a member selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 19, 20, 21 and 22.

In another such embodiment, the present invention specifically encompasses an isolated polypeptide comprising a polypeptide having an amino acid sequence with at least 90 percent identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 11, 12, 23, 24, 25, 26, 27 and 28, preferably at least 95 percent, more preferably at least 98 percent and most preferably where the amino acid sequence is selected from the group consisting of SEQ ID NO: 10, 11, 12, 23, 24, 25, 26, 27 and 28.

The present invention also encompasses embodiments where the agents identified by the methods of the invention, or useful in the methods of the invention, may be present in the form of a composition for treating a disease of iron metabolism comprising a therapeutically effective amount of a polypeptide of the invention, or a pharmaceutically active fragment thereof, in a pharmaceutically acceptable carrier. In accordance therewith, the present invention specifically contemplates a method for treating a disease of iron metabolism comprising administering to a patient in need thereof a therapeutically effective amount of such a composition. In an embodiment thereof, the disease is juvenile hemochromatosis.

In a further aspect, the present invention relates to a method for identifying an agent for the treatment of a disease of iron metabolism, comprising:

a) administering to an animal an agent found to have activity using a method as disclosed herein, and

b) detecting in said animal a change which is indicative of a change in iron metabolism due to said administering,

thereby identifying an agent for the treatment a disease of iron metabolism.

5 Preferably, the animal is a mammal, such as a human being. In specific embodiments, the change in iron metabolism may be a change in storage tissue distribution of iron.

In a preferred embodiment of the invention, the compound identified which modulates HFE2A is selective for HFE2A ahead of related genes or
10 proteins, and therefore does not significantly modulate the activity of such other related genes or proteins by direct interaction.

In a further aspect, the present invention relates to a method for treating a condition in an animal afflicted with a disease of iron metabolism comprising administering to said animal an effective amount of an agent first identified by an
15 assay method of the invention. Preferably, said animal is a human patient, such as a patient afflicted with a chronic disease of iron metabolism.

In a further aspect, the compounds identified by the assays disclosed herein, and the methods of treating patients with such compounds, are applied to alternative or additional indications beyond diseases of iron metabolism,
20 which are found to be treatable by modulating HFE2A activity.

In a further aspect, the present invention relates to compounds that modulate HFE2A that may now be identified by those skilled in the art. These compounds include antibodies, antisense compounds, gene therapy vectors and proteins, and small molecule organic compounds.. The invention also
25 comprises the use of these compounds for treatment of diseases associated with aberrant HFE2A activity. In one embodiment, the use of the compounds for treatment of disease of iron metabolism.

In another aspect, the present invention relates to a method for producing a product comprising identifying an agent according to the process
30 of the invention wherein said product is the data collected with respect to said agent as a result of said process and wherein said data is sufficient to convey the chemical structure and/or properties of said agent.

In another aspect, the present invention relates to diagnostic and pharmacogenomic compositions, kits and methods which identify the presence or absence in a patient of one or more mutations in a polynucleotide or a polypeptide corresponding to SEQ ID NOs: 1-12, including those specific mutations identified at SEQ ID NOs 14, 16, and 18, and other mutations that may be subsequently discovered to be relevant. This embodiment is useful in diagnosing the presence or absence of juvenile hemochromatosis. It is also useful for diagnosis of adult-onset hemochromatosis, and for the prediction of onset and severity thereof.

Figure 1 illustrates alternative splice variants that are generated during transcription of the HFE2A gene. For convenience, the nucleotide sequences of the coding exons are set out as follows:

SEQ ID NO.	Description
1	Sequence of Exon 1
2	Sequence of Exon 2
3	Sequence of Exon 3a
4	Sequence of Exon 3b
5	Sequence of Exon 4

The alternative splice variants generated from the gene produce at least 5 transcripts. The nucleotide sequence of each of transcripts 1 to 4, corresponding to a cDNA sequence (or a processed mRNA sequence if T is converted to U) is set out as follows:

SEQ ID NO.	Description
6	Wild-Type Human HFE2A putative cDNA - Transcript 1 (exon 1, 4)
7	Wild-Type Human HFE2A putative cDNA - Transcript 2 (exon 1, 3a, 4)
8	Wild-Type Human HFE2A putative cDNA - Transcript 3 (exon 1, 3b, 4)
9	Wild-Type Human HFE2A putative cDNA - Transcript 4 (exon 1, 2, 3b, 4)

Each of these four transcripts of the HFE2A gene may be translated into an HFE2A polypeptide. Transcripts 1 and 2 generate the same full length proteins, hence there are 3 full-length proteins of 200 amino acids (a.a.), 313 a.a. and 426 a.a., respectively. The amino acid sequence generated from each transcript is set out as follows:

SEQ ID NO.	Description
10	Wild-Type Human HFE2A Polypeptide – Protein 1 (Transcripts 1 & 2)
11	Wild-Type Human HFE2A Polypeptide – Protein 2 (Transcript 3)
12	Wild-Type Human HFE2A Polypeptide – Protein 3 (Transcript 4)

The longest cDNA sequence (Transcript 4, SEQ ID No. 9) and the longest protein sequence (Protein 3, SEQ ID No. 12) have been used as the basis for the sequencing numbering convention used in the instant specification.

Aspects of the sequence of HFE2A have been previously published in various sources, including the following: Homo sapiens Official Gene Symbol and Name: LOC148738; NCBI LocusID: 148738; Other Names: ENSG00000168509 (Ensembl v. 12.31.1), NM_145277 (RefSeq); Genomic Location: 142000393 - 142004657 bp on chromosome 1 (Assembly: NCBI 31 assembly of the human genome, Freeze Date: November 2002) (Ensembl Version for reference sequences: Ensembl v. 12.31.1.) An incomplete fragment of HFE2A is contained in PCT publication WO 02/051438 where it was listed as RGM3 and implicated as a Repulsive Guidance Molecule in neuronal development (3 amino acids, 9 nt missing from 5' coding end).

A positional cloning strategy, set out in Example 1 below, was used to confirm that chromosomal region 1q21 was highly associated with juvenile hemochromatosis. Candidate genes were investigated to determine if mutations were present. The HFE2A gene described herein was determined to contain a variety of deleterious mutations as follows:

Table 1.

Mutation	Type	Sequence
c.296G>T,p.G99V	WT	acctgccgGggacctcgcc (SEQ ID NO: 31)
	MT	acctgccgTggacctcgcc (SEQ ID NO: 32)
c.842T>C,p.I281T	WT	gctgcctacaTtggcacaact (SEQ ID NO.13)
	MT	gctgcctacaCtggcacaact (SEQ ID NO.14)
c.959G>T,p.G320V	WT	tgtgtggggGtgccctcca (SEQ ID NO.15)
	MT	tgtgtggggTtgccctcca (SEQ ID NO.16)
c.1079delC,p.C361fsX366	WT	tactccattCctgtgtctt (SEQ ID NO.17)
	MT	tactccatt_ctgtgtctt (SEQ ID NO.18)
c.976C>T, p. R326X	WT	tccaagtcagCgactctctg (SEQ ID NO. 29)
	MT	tccaagtcagTgactctctg (SEQ ID NO. 30)

- 5 Table 1 shows genetic variations identified in HFE2A (ENSE00001277351). The cDNA position of the mutation is represented by the number in the first column (i.e.; c.665). The mutations are numbered starting from the initiating ATG codon in ENST00000306561 (transcript 4) (SEQ ID NO. 9). For each variation ten bases of sequence on either side is presented with the wildtype
- 10 (WT) and mutant (MT) base capitalized.

Table 2.

Variation	JH3	JH4	JH5	JH6	JH7	JH8	JH9	JH10	JH11	JH12
c.296G>T,p.G99V							TT			
c.842T>C,p.I281T		CC								
c.959G>T,p.G320V	TT		TT	TT	TT			TT	GT	TT
c.1079delC,p.C361fsX366						del/del				
c.976C>T, p. R326X									TC	

Table 2 shows genetic variations identified in Juvenile Hemochromatosis families. The first column describes the variation, the other columns present the genotype of each chromosome at the site of mutation of a proband in each family. JH3, 4, 5, 6, 7, 8, 9, 10 and 12 are homozygous for the variation.

5 JH11 is a compound heterozygote with two variations.

Segregation of the indicated mutations in HFE2A with affected HFE2A patients has now been confirmed in all affecteds in the families identified in Table 2. The variation is not found in 128 European and 37 Greek control (unaffected) individuals. Thus, the presence of 7 families having one coding
10 change resulting in a G320V, one family having a unique coding change resulting in a I281T, and two other families having a premature truncation of this protein is convincing evidence that mutations in HFE2A (Gene 3 (LOC148738) ENSG00000168509 v.12.31.1) cause Juvenile Hemochromatosis.

15 Another variation occurred in control samples (i.e. unrelated persons not affected with JH). Two of 128 Dutch controls are heterozygous for c.1207G>A, p.V403I. Since it was heterozygous in these two samples, no JH phenotype would be expected to be apparent, nor is it found in these individuals. This variation could be a single nucleotide polymorphism (SNP)
20 in the Dutch population which is not deleterious. Alternatively, it may be a potentially causal mutation of JH were it to appear in the homozygous form. At this point it is just a SNP, but it may be useful for diagnostic, or therapeutic purposes.

A significantly conserved genomic DNA promoter nucleic acid
25 sequence for HFE2A has been identified in humans, mouse and rat as follows:

SEQ ID NO.	Description
19	Promoter sequence – human
20	Promoter sequence – mouse
21	Promoter sequence – rat

Alignment of the promoter sequences in Figure 2 shows the high degree of conservation between species in the regulatory region. Sequence conservation is substantially lost about 670 nt 5' to the transcription initiation site in the human sequence.

5 Genomic sequence: the full human genomic sequence illustrating the nucleic acid sequence around HFE2A is set forth at SEQ ID NO. 22. Exons are indicated in capital letters.

10 In accordance therewith, a gene useful in the methods of the invention comprises a polynucleotide corresponding to a polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 19, 20, 21 and 22.

In another aspect, the present invention relates to a method for identifying an agent that modulates HFE2A gene expression, comprising:

15 (a) contacting a test compound with a genetic construct comprising a reporter gene operably linked to an HFE2A promoter under conditions supporting expression of said reporter gene;

 (b) determining a change in expression of said reporter gene as a result of said contacting,

20 wherein a change expression identifies said test compound, or confirms said test compound, as an agent that modulates HFE2A gene expression.

25 In preferred embodiment thereof, the modulation is a decrease or increase in expression, especially transcription, of said reporter gene and includes embodiments where the HFE2A promoter is a mammalian HFE2A promoter, preferably a mouse, rat or human HFE2A promoter. In a highly preferred embodiment, the promoter has a nucleotide sequence of SEQ ID NO: 19.

30 In a preferred embodiment, the expression of said reporter gene is determined by measuring the activity of an enzyme, such as where the reporter gene encodes a protein having a readily measurable enzyme activity.

As used herein, the term "identifying" can include first identifying said test compound as an agent that modulates gene expression or a polypeptide activity (i.e., where the agent was not previously known or suspected of having this activity) or can include confirming such activity (where the agent was already suspected of having this activity but was not clearly shown to have such activity) by performing one or more of the assays of the invention. For example, where an agent has previously been implicated in modulation of HFE2A gene or polypeptide activity, or where such agent was suspected, or otherwise believed to be, an agent capable of altering, modulating, or affecting iron metabolism, such as where the agent has been implicated in regulating iron metabolism, and the activity of such agent is confirmed to have such activity utilizing a method of the invention, such agent is deemed to have been identified as having the indicated activity.

In another aspect, the present invention relates to a method for identifying an agent that modulates HFE2A polypeptide activity, comprising;

- (a) contacting a chemical agent with said HFE2A polypeptide under conditions promoting protein:protein interactions, and/or
 - (b) contacting a chemical agent with said HFE2A polypeptide under conditions promoting HFE2A ligand HFE2A receptor interactions, and/or
 - (c) contacting a chemical agent with said HFE2A polypeptide under conditions promoting modifications in lipid composition, and/or
 - (d) contacting a chemical agent with said HFE2A polypeptide under conditions promoting alterations in associated second messenger signaling
- wherein such interaction, alteration or modification indicates modulation and thereby identifying the chemical agent as an agent that modulates HFE2A polypeptide activity.

HFE2A activity may be mediated through alteration of an associated second messenger.

In one highly useful embodiment, the genetic construct is in a cell, preferably a mammalian cell, most preferably a recombinant cell, such as where the mammalian cell is a macrophage, liver cell, hepatocyte, intestinal cell, inflammatory cell, liver cell, hepatocyte, intestinal cell, hematopoietic cell, pancreatic cell, skeletal muscle cell or a nervous system cell.

Table 3 below sets forth other polymorphisms that have been identified in the HFE2A gene of control individuals (i.e. those with no clinical manifestation of Juvenile Hemochromatosis or other iron metabolism disorder). These polymorphisms, and others that may be discovered by those skilled in the art, may be useful for diagnostic or therapeutic or other purposes.

TABLE 3

Mutation	Type	Sequence
c.1-15C>G, na	WT	gcctgggaaaCctggctggat (SEQ ID NO: 33)
	MT	gcctgggaaaGctggctggat (SEQ ID NO: 34)
c.98-6C>G,intronic 2-3	WT	tcccttctgtCtttagctcat (SEQ ID NO: 35)
	MT	tcccttctgtGtttagctcat (SEQ ID NO: 36)
c.205_206insAGG, p.G69_70insG	WT	gaggaggagg—ccgggggtgga (SEQ ID NO: 37)
	MT	gaggaggaggAGGccgggggtgga (SEQ ID NO: 38)
c.432C>G, p.A144A	WT	gcctccctgcCccggaccctt (SEQ ID NO: 39)
	MT	gcctccctgcGccggaccctt (SEQ ID NO: 40)
c.483C>A, p.P161P	WT	atggtcgtccCccgggggttct (SEQ ID NO: 41)
	MT	atggtcgtccAccgggggttct (SEQ ID NO: 42)
c.488G>C, p.G163A	WT	cgtcccccgGgttcttgcac (SEQ ID NO: 43)
	MT	cgtcccccgGgttcttgcac (SEQ ID NO: 44)
c.569C>A, p.A190D	WT	gtccaaggagCttggcctcta (SEQ ID NO: 45)
	MT	gtccaaggagAttggcctcta (SEQ ID NO: 46)
c.627G>T, p.A209A	WT	cccccatggcGttgggggcca (SEQ ID NO: 47)
	MT	cccccatggcTttgggggcca (SEQ ID NO: 48)
c.682C>A, p.Q228K	WT	taagaacatgCaggaatgcat (SEQ ID NO: 49)
	MT	taagaacatgAaggaatgcat (SEQ ID NO: 50)
c.929C>G, p.A310G	WT	gccttctcagCtgaacaggac (SEQ ID NO: 51)
	MT	gccttctcagGtgaacaggac (SEQ ID NO: 52)
c.1207G>A, p.V403I	WT	agatgctgggGttcctctttc (SEQ ID NO: 53)
	MT	agatgctgggAttcctctttc (SEQ ID NO: 54)

Capital letter indicates site and nature of polymorphism. WT = wild-type; MT = mutation.

Similarity to other Human genes

5 Figure 3 illustrates an alignment between HFE2A and 2 related proteins found in the human genome. The similarity suggests that some functionality may be shared or similar between these proteins.

Table 4 shows a comparison of Human LOC148738 426 aa protein sequence (Protein3) to Human Paralogs* using BLAST**

10 Table 4.

Paralog	Score	Alignment (a.a.)	Identity %	Positive %	Gaps %
Human RGM (SEQ ID No. 23)	370 bits (939)	432	48%	60%	12%
ENSESTP00000023393 (SEQ ID No. 24)	333 bits (844)	444	42%	55%	13%

* ENSESTP00000023393 (Ensembl) on Chromosome 5 and Human Repulsive Guidance Molecule (Human RGM) (NCBI: NP_064596.1) on chromosome 15

**Sequence comparison using "BLAST 2 Sequences" (Tatiana A. Tatusova, Thomas L. Madden (1999), FEMS Microbiol Lett. 174:247-250) Parameters: blastp, BLOSUM62 matrix, open gap penalty of 11, extension gap penalty of 1, gap x_dropoff of 50, word size of 3, expect 10

Conservation of HFE2A in other organisms.

2. Homologs of human HFE2A gene were found in mouse (Mus musculus), rat (Rattus norvegicus) and fish (Takifugu rubripes ("Fugu")). Figure 4 sets out a sequence comparison at the nucleotide level of these sequences. The high degree of conservation of these sequence is shown in

Table 5, which shows a comparison of Human LOC148738 426 aa protein sequence (Protein3) to Orthologs* using BLAST**

5 Table 5.

SPECIES	Score	Alignment (a.a.)	Identity %	Positive %	Gaps %
Mouse SEQ ID No. 25	758 bits (1936)	420	88%	90%	0%
Rat SEQ ID No. 26	752 bits (1920)	426	86%	89%	0%
Fugu SEQ ID No. 27	336 bits (853)	383	46%	61%	4%

* Organism sequences: Mouse (Ensembl: ENSMUSESTP00000016634), Rat (Translated from NCBI: AK098165.1) and Fugu (Ensembl: SINFRUP000000138308).

**Sequence comparison using "BLAST 2 Sequences" (Tatiana A. Tatusova, Thomas L. Madden (1999), FEMS Microbiol Lett. 174:247-250)
 15 Parameters: blastp, BLOSUM62 matrix, open gap penalty of 11, extension gap penalty of 1, gap x_dropoff of 50, word size of 3, expect 10

Comparison of human HFE2A with chicken RGM is shown in Figure 5. The 426 aa sequence translation of Human LOC148738 (Protein3 identical to
 20 ENSP000000304614) shares significant sequence homology with Chicken_ Repulsive Guidance Molecule (RGM) (Translation of NCBI: AY128507.1). Chicken RGM amino acid sequence is listed at SEQ ID No. 28. Using "BLAST 2 Sequences" (Tatiana A. Tatusova, Thomas L. Madden (1999), FEMS Microbiol Lett. 174:247-250) 395 of the residues align with 46%
 25 Identity, 61% Positives and 9% Gaps. The two proteins also share a N-terminal signal peptide, a RGD tri-amino acid motif that could be involved in cell attachment, a site identified as a possible cleavage site in Chicken RGM,

a partial (~57%) von Willebrand Type D domain, and a predicted N-Glycosylation site. Both proteins are also predicted to have GPI modifications at the C-terminus .

5 A visual overview of similarities shared between human HFE2A and homologs in mouse, rat and fugu, as well as sequences from Macac RGM, Chicken RGM, Xenopus RGM and C.Elegans NP are shown in Figure 6. This degree of similarity illustrates that similar genes or proteins from other species may be useful for various embodiments of the invention. The protein also has the sequence *Arg-Asn-Arg-Arg*³³⁵ representing the consensus cleavage site
10 (*Arg-X-Lys/Arg-Arg*) for the proprotein convertase furin (Molloy, S.S. et al. J. Biol. Chem., 267, 16396-16402, (1992)) which would result in cleavage between positions 335 and 336.

A comparison of sequences between related genes from human, mouse, rat, chicken and zebrafish is shown at Figure 6B. Orthologs of the
15 human HFE2A protein are found in mouse, rat and zebrafish (Fig. 6B). Sequence comparison shows that human HFE2A is >85% identical with the mammalian orthologs, and ~45% identical to the fish ortholog. The 426 amino acid translation of HFE2A also shares significant sequence similarity with the Repulsive Guidance Molecule (RGM or RGMA) of human (48% identity) and
20 chicken (46% identity) (Fig. 6B). In humans there is also a third RGM-like gene, RGMB, whose biological function is currently unknown.

HFE2A Polypeptide Function

This invention teaches the important discovery that HFE2A is a critical
25 regulator of iron metabolism. Exactly how it is involved in this process remains to be fully clarified. Important information about the activity of this protein can be determined based on the analysis of protein domains.

The 426 aa LOC148738 gene product (Protein3) has structural features consistent with a GPI (Glycosylphosphatidylinositol) anchored protein
30 (Fig 7a) including a N terminal hydrophobic signal peptide for access to the Endoplasmic Reticulum, where GPI anchor addition occurs (residues 1-35 Fig. 7b) and a C terminal hydrophobic domain/GPI addition signal sequence

(residues 403-425 Fig. 7c) (Udenfriend S and Kodukula K Ann Rev Biochem 1995). The GPI predicting program big-Pi predictor predicts that this gene product is GPI modified, and that either amino acids 399 or 400 can act as the omega site (Eisenhaber et al., JMB, 292 (3), 741-758, 1999). Other features identified are a RGD – cell attachment tri amino acid motif (residues 98-100) (Ruoslahti, E. Annu. Rev. Cell Dev. Biol. 12, 697-715 (1996)) and a partial von Willebrand factor type D domain. von Willebrand factor type D domains are required for multimerization of von Willebrand factor (residues 167-253) (Jorieux, S. et al., Blood 1998 Dec 15;92(12):4663-70). In addition, the protein has a possible proteolytic cleavage site identified by sequence comparison with Chicken Repulsive Guidance Molecule (RGM) between residues 172 and 173 (Fig. 7e) (Monnier, P.P. et al. Nature 419, 392-394, 2002). Also present but not shown are N-glycosylation and O-glycosylation sites which appear to be consistent with consensus sequences.

Figure 8 shows a protein domain analysis of HFE2A from a nucleotide/amino acid perspective. Features of the sequence are illustrated therein.

Further aspects of HFE2A Polypeptide function at the biochemical level may be determined by those skilled in the art using standard techniques. It is clear from the instant invention that HFE2A Polypeptide is directly involved in iron transport, as the absence of this gene in humans leads to the condition of juvenile hemochromatosis (type 2A) or HFE2A.

Sixteen human tissues were examined for *HFE2A* expression by probing Northern blots with a probe from exon 4. Significant *HFE2A* expression was detected in liver, heart (especially atria) and skeletal muscle (data not shown).

Based on publicly available ESTs (expressed sequence tags), fragments of this gene has also been found to be expressed in the following tissues:

Human HFE2A: skeletal muscle, liver, sciatic nerve, Liver and Spleen, prostate, heart;

Mouse HFE2A: mammary gland, heart, tongue, liver, xiphoid cartilage, medulla oblongata

Rat HFE2A: brain, ovary, placenta, kidney, lung, liver, heart, muscle, spleen

5 Therefore the HFE2A gene appears to be widely expressed in many tissues, but at reasonably low levels.

While not wishing to be bound to any particular mechanism of action of how HFE2A mutation causes juvenile hemochromatosis, or leads to adult onset hemochromatosis, it is possible to speculate on different roles the
10 gene/protein of the invention may play in iron metabolism. For instance, the HFE2A protein may lie upstream or downstream of hepcidin in the iron metabolism pathway. One possibility is that the protein is the hepcidin receptor or a co-factor for the hepcidin receptor. Another possibility is that HFE2A functions in the transcription, translation and/or processing of
15 hepcidin, and is necessary for proper functioning of hepcidin. HFE2A may be a hepcidin interacting protein. An alternate function is that the HFE2A protein may be a secreted factor from the bone marrow or liver, acting in a paracrine fashion, as a hormone or hormone-like compound regulator of hepcidin levels.

These possible mechanisms of action are suggestive for further
20 exploration of the protein, but are not intended to be limiting on the scope of claims included below. In all of these scenarios, the functional consequences are the same, i.e. loss of function of HFE2A results in loss of the body's capacity to control iron metabolism through normal hepcidin function, thus precipitating the development of juvenile hemochromatosis, or adult onset hemochromatosis
25 (possibly where other factors in the hepcidin/HFE2A metabolic pathway are not fully functional). Thus, modulating the activity of HFE2A is a method to regulate serum levels, biodistribution, and/or metabolism of iron in the body.

Modulation of HFE2A is also a method for treating diseases which are not directly related to iron or iron metabolism. A function for HFE2A unrelated to
30 its proposed role in iron metabolism is that of regulating blood volume. HFE2A is highly expressed in heart, especially in the right atrium, and therefore it is possible that HFE2A plays a hematological role, such as in sensing circulating

blood volume and the regulation of blood volume. Alternatively, HFE2A may play a paracrine function in the heart protecting local myocytes from iron related disease. Compounds which modulate the activity of HFE2A are therefore useful in treating or preventing hematological disorders, cardiac disorders (including but not limited to cardiac failure, cardiomyopathy, disorders of fluid imbalance, and arrhythmias), and hormonal disorders. Also important, because hepcidin levels are stimulated in bacterial infections, inflammation, response to LPS injection, etc, HFE2A is a suitable therapeutic target for mediating aspects of these disorders, and could be important in treatment of bacterial sepsis, etc.

This invention establishes that the function of HFE2A is an essential regulator of iron in the human body, regardless of its exact mechanism of action. It is therefore a desirable drug target for treating diseases of iron metabolism in animals. For example, because HFE2A is directly implicated in JH and adult onset hemochromatosis according to this invention, the inventors recognize that JH and other diseases where iron metabolism is defective may be treatable by administering a chemical modulator of HFE2A. The disease may not necessarily be related to aberrant HFE2A gene or protein activity. For example, a compound which modulates HFE2A activity may compensate for insufficiencies in other aspects of the iron metabolism pathway. Or, a modulator of HFE2A may be used to treat a disease which is indirectly responding to iron levels in the blood.

As used in this disclosure the phrase "disease of iron metabolism" is therefore to be construed in its broadest context. This includes diseases where aberrant iron metabolism directly causes the disease, or where iron blood levels are dysregulated causing disease, or where iron dysregulation is a consequence of another disease, or where diseases can be treated by modulating iron levels, etc. More specifically, a disease of iron metabolism according to this disclosure includes iron overload disorders, iron deficiency disorders, disorders of iron biodistribution, other disorders of iron metabolism and other disorders potentially related to iron metabolism, etc. Even more specifically diseases of iron metabolism includes hemochromatosis, ferroportin mutation hemochromatosis, transferrin receptor 2 mutation hemochromatosis, juvenile hemochromatosis, neonatal hemochromatosis, hepcidin deficiency, transfusional iron overload,

thalassemia, thalassemia intermedia, alpha thalassemia, sideroblastic anemia, porphyria, porphyria cutanea tarda, african iron overload, hyperferritinemia, ceruloplasmin deficiency, atransferrinemia, congenital dyserythropoietic anemia, anemia of chronic disease, anemia, hypochromic microcytic anemia, iron-
5 deficiency anemia, conditions with hepcidin excess, Friedreich's Ataxia, gracile syndrome, Hallervan Spatz disease, Wilson's disease, pulmonary hemosiderosis, hepatocellular carcinoma, cancer, hepatitis, cirrhosis of liver, pica, chronic renal failure, insulin resistance, diabetes, atherosclerosis, neurodegenerative disorders, multiple sclerosis, Parkinson's Disease,
10 Huntington's Disease, Alzheimer's Disease.

In particular, a modulator of HFE2A can usefully treat anemia of chronic disease. Worldwide, anemia of chronic disease (ACD, also know as Inflammatory Anemia) is the second most common form of anemia. ACD represents the most common form of anemia in hospitalized patients. ACD is an
15 acquired disorder seen in patients with a variety of conditions including infection, malignancy and chronic inflammation. It is characterized by retention of iron by macrophages and decreased intestinal iron absorption, which leads to reduced iron availability for erythropoiesis. Early in the course of their disease, patients with ACD have a mild, normocytic anemia due to impaired iron recycling. Later,
20 due to the reduced intestinal absorption they become frankly iron deficient with a hypochromic microcytic picture. Initial studies examining the role of hepcidin in ACD show that excessive hepcidin production underlies ACD.

Loss-of-function of murine hepcidin leads to severe iron overload, mimicking the biochemical and clinical phenotype of JH. In contrast, in both
25 animal models and human disease, hepcidin overexpression leads to macrophage iron retention and an iron deficient phenotype typical of the iron disturbances found in ACD. Existing therapy for ACD is mainly targeted to treating the underlying disorder, with no efficacious treatment specifically directed to amelioration of the iron phenotype. Therefore, therapeutic strategies
30 to reduce hepcidin production, such as by inhibition of HFE2A represent an important novel approach to treating the iron disturbances seen in ACD.

In some cases the diseases and disorders included in the definition of "disease of iron metabolism" are not typically identified as being iron related. It is recognized by the instant invention that based on the tissue distribution of HFE2A (hemojuvelin) and its related protein, hepcidin, that iron metabolism may play a significant role in these disease processes. For example, it has recently been shown that hepcidin is very highly expressed in the murine pancreas suggesting that diabetes (Type I or Type II), insulin resistance, glucose intolerance and other disorders may be ameliorated by treating underlying iron metabolism disorders: (See Ilyin, G. et al. 2003 Febs. Letters 542 22-26). As such, these diseases are encompassed under the broad definition.

Method of Treatment Using HFE2A as a Therapeutic Target.

The discovery that mutations in HFE2A relate to clearly definable physiological outcomes in humans (namely juvenile hemochromatosis), now allows the inventors to establish, for the first time, that hemojuvelin, the HFE2A Gene and HFE2A Polypeptide are useful as therapeutic targets in humans for the treatment of diseases of iron metabolism. The words "therapeutic target" are intended to mean that therapeutic intervention is achieved with therapeutic agents that modulate the activity of the gene or protein. "Modulate" means to increase, to decrease, or to otherwise change the activity. Standard industrial processes are available to those skilled in the art to confirm the identity of the therapeutic agents which modulate the activity of the gene or protein, some of which are set out below.

In accordance with the foregoing, the present invention relates to a method for treating a disorder comprising administering to a person in need of such treatment an effective amount of a selective HFE2A agonist or antagonist, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity.

In a preferred embodiment, said disorder is a disease of iron metabolism. In a further preferred embodiment, said administering is by oral or intravenous means.

Use of the HFE2A in Screening Assays for Identifying Therapeutic Agents and Classes of Potential Therapeutic Agents.

The present invention readily affords different means for identification of agents for treating diseases of iron metabolism according to their ability to modulate the activity of HFE2A. Exemplary assay methods useful for the identification of such compounds are detailed herein, although those skilled in the art will be aware of alternative means.

In one series of embodiments described in some detail below, assay methods involve testing libraries of chemical compounds, either one at a time or in combinations, in an assay format designed to measure a biological activity related to HFE2A. Those library compounds that modulate the biological activity in the desired fashion are thereby identified as therapeutic agents of the invention. In effect, a wide variety of compounds are sequentially tested against the assay to determine whether they influence a measurable biological activity of the assay. Assays may be based one or more of the diverse measurable biological activities of a gene or polypeptide corresponding to HFE2A.

"HFE2A activity" or "HFE2A biological activity" as used herein, especially relating to screening assays, is to be interpreted broadly and contemplates all directly or indirectly measurable and identifiable biological activities of the HFE2A gene, gene products and HFE2A Polypeptide. Relating to the purified HFE2A Polypeptide protein, HFE2A Polypeptide activity includes, but is not limited to, all those biological processes, interactions, binding behavior, binding-activity relationships, pKa, pD, enzyme kinetics, stability, and functional assessments of the protein. Relating to HFE2A Polypeptide activity in cell fractions, reconstituted cell fractions or whole cells, these activities include, but are not limited the rate at which HFE2A Polypeptide performs any measurable biological characteristic and all measurable consequences of these effects, including cell growth, development or behavior and other direct or indirect effects of HFE2A Polypeptide activity. Relating to HFE2A genes and transcription, HFE2A activity includes the rate, scale or scope of transcription of genomic DNA to generate RNA; the effect of regulatory proteins on such transcription, the

effect of modulators of such regulatory proteins on such transcription; plus the stability and behavior of mRNA transcripts, post-transcription processing, mRNA amounts and turnover, all measurements of expression and translation of the mRNA into polypeptide sequences, and all measurements of protein
5 expression levels or dynamics. Relating to HFE2A activity in organisms, this includes but is not limited biological activities which are identified by their absence or deficiency in disease processes or disorders caused by aberrant HFE2A biological activity in those organisms. Some of the known or suggested biological activities are set out in the description of HFE2A
10 provided in the specification, however those skilled in the art will be able to identify further measurable activities of HFE2A with routine techniques. Broadly speaking, HFE2A biological activity can be determined by all these and other means for analyzing biological properties of proteins and genes that are known in the art.

15 It is also recognized that those skilled in the art may prefer to use forms of HFE2A corresponding to the sequences disclosed herein, although not necessarily the same. For example, while screening assays preferably employ HFE2A from human, mouse, rat or fugu, other assays may utilize HFE2A from a different organism, preferably a vertebrate, and most preferably from a
20 mammalian species. Thus the invention encompasses the use of, including but not limited to, sheep, dog, cow or horse HFE2A, for the same purposes as set out more specifically herein for human HFE2A. The shared technical features of these forms of HFE2A, are that, when expressed, they have similar biological activity, and that they share functional similarity with HFE2A,
25 as the case may be, such as may be determined by those skilled in the art. The HFE2A gene and/or HFE2A Polypeptide according to the invention may also be obtained from other mammalian species, other vertebrates, invertebrates and microorganisms based on the disclosure herein.

Thus, the polynucleotides for use in the screening assays of the
30 invention that "correspond to" the polynucleotide encoding HFE2A (processed or unprocessed, including naturally occurring splice variants and alleles) are at least 40%, preferably at least 50%, more preferably at least 60%,

especially at least 70%, even more preferably at least 80%, or even at least 85%, most preferably at least 90%, or even at least 95%, or most especially at least 98%, with the especially preferred embodiment of identical to, and especially having the sequence of, an RNA that would be encoded by, or be
5 complementary to, such as by hybridization under reasonably stringent conditions, with an HFE2A polynucleotide (SEQ ID NO: 1-9, or 13-22.). In addition, HFE2A protein sequences encoding the same polypeptides as any of the nucleic acid sequences corresponding to HFE2A, regardless of the percent identity of such sequences, are also specifically contemplated by any
10 of the methods of the present invention that rely on any or all of said sequences, regardless of how they are otherwise described or limited. Thus, any such sequences are available for use in carrying out any of the methods disclosed according to the invention. Such sequences also include any open reading frames, as defined herein, present within an HFE2A polynucleotide.

15 Because of the processing that may take place in transforming the initial RNA transcript into the final mRNA, the sequences disclosed herein may represent less than the full genomic sequence. They may also represent sequences derived from alternate splicing of exons. Consequently, the genes present in the cell (and representing the genomic sequences) and the
20 sequences disclosed herein, which are mostly cDNA sequences, may be identical or may be such that the cDNAs contain less than the full complement of exons found in the genomic sequence. Such genes and cDNA sequences are still considered corresponding sequences because they both encode similar RNA sequences. Thus, by way of non-limiting example only, a gene
25 that encodes an RNA transcript, which is then processed into a shorter mRNA, is deemed to encode both such RNAs and therefore encodes an RNA corresponding to an HFE2A sequence as disclosed herein. (Those skilled in the art understand that the word "encode" and its derivatives mean, in this field "can be transcribed into" or "can be translated into"). Thus, the
30 sequences disclosed herein correspond to genes contained in the cells and are used to determine relative levels of transcription because they represent the same sequences or are complementary to RNAs encoded by these

genes. Such genes also include different alleles and splice variants that may occur in the cells used in the processes of the invention.

As used herein, the term "percent identity" or "percent identical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:

$$\text{Percent Identity} = 100 [1 - (C/R)]$$

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the hereinabove calculated Percent Identity is less than the specified Percent Identity.

Where context indicates that sequences have been analyzed using the NCBI Blast tools, reports of sequence score, alignment, identity%, positive% and gaps% have been generated based on these calculations: For the segment pair, the alignment score is the sum of the scoring matrix values. The theory of amino acid substitution matrices is described in [1], and applied to

DNA sequence comparison in [2]. The number of positives is the number of residues for which the alignment score has a positive value. Experimentation has shown that the BLOSUM-62 matrix [3] is among the best for detecting most weak protein similarities. [1] Altschul, S.F. (1991) "Amino acid substitution matrices from an information theoretic perspective." J. Mol. Biol. 219:555-565. [2] States, D.J., Gish, W. & Altschul, S.F. (1991) "Improved sensitivity of nucleic acid database searches using application-specific scoring matrices." Methods 3:66-70. [3] Henikoff, S. & Henikoff, J.G. (1992) "Amino acid substitution matrices from protein blocks." Proc. Natl. Acad. Sci. USA 89:10915-10919.

10 As used herein, the terms "portion," "segment," and "fragment," when used in relation to polypeptides, refer to a continuous sequence of nucleotide residues, sequence forms a subset of a larger sequence. Such terms include the products produced by treatment of said polynucleotides with any of the common endonucleases, or any stretch of polynucleotides that could be synthetically synthesized. These may include exonic and intronic sequences of
15 the corresponding genes.

The instant invention provides numerous assays which measure an activity of HFE2A and are useful for the testing of compounds to identify which ones affect such activity. In terms of formatting the assays, the assays
20 may use whole cells, cell extracts or reconstituted cell extracts, or purified or semi-purified proteins, or they may be larger scale tissue or whole animal assays. Common assays use measurements based on fluorescence, luminescence, radioactivity, or other measures of protein or gene transcript levels, amounts, or stability. Polypeptide assays may also include those
25 wherein the HFE2A polypeptide is attached to a solid support, such as a resin or other polymer, especially where this is part of a column procedure for determining activity. Alternatively, batch procedures may also be used.

In one aspect, the present invention relates to a method for identifying an agent that modulates the activity of an HFE2A polypeptide, comprising:

30 a) contacting a test compound with an HFE2A polypeptide and under conditions supporting an activity of said polypeptide; and

b) determining a change in said activity of said HFE2A polypeptide as a result of said contacting,

wherein a change in the activity identifies said test compound as an agent that modulates the activity of an HFE2A polypeptide.

5 In a preferred embodiment, said gene has the sequence of SEQ ID NO: 1 - 9.

In a preferred embodiment, the observed change in activity in step (b) is a decrease or an increase in activity, most preferably wherein said change in activity is the result of binding to said polypeptide by said chemical agent of
10 step (b). In a preferred embodiment, such agents are useful for treating a disease of iron metabolism.

In other preferred embodiments, the polypeptide is part of an intact cell, preferably a mammalian cell, and which may be a recombinant cell. For HFE2A, cells of greatest interest include macrophages, hepatocytes, intestinal cells,
15 heart cells (especially atrial cells), pancreatic cell, skeletal muscle cell and cells of the bone marrow, although cells from other tissues may be employed. In one such embodiment, said cell has been engineered to comprise said polypeptide, including by genetic engineering, especially where the cell does not possess the polypeptide absent said engineering. Thus, the present invention specifically
20 contemplates embodiments in which the cell is engineered by other than genetic engineering, such as where the activity of a polypeptide is to be enhanced and the cell has been engineered to contain, or have on its surface, said polypeptide but wherein the polypeptide is present due to physical insertion of the polypeptide into the membrane or cytoplasm of the cell and not through
25 expression of a gene contained in the cell. Methods well known in the art, such as use of polyethylene glycol, viruses, and the like, are available to effect such insertions and the details of such procedures need not be further described herein.

In one preferred embodiment of such method, the polypeptide is a
30 polypeptide that reacts with an antibody that reacts with, or is specific for, a polypeptide having an amino acid sequence at least 95% identical to, more preferably at least 98% identical to, the sequence of SEQ ID NO: 10 - 12 and

where any difference in amino acid sequence is due only to conservative amino acid substitutions. In an especially preferred embodiment, the polypeptide has the amino acid sequence of SEQ ID NO: 10 - 12.

5 The HFE2A Polypeptide assays of the invention may employ compound screening technology such as (but not limited to) the ability of various dyes to change color, or fluorescent signaling/quenching in response to changes in assay conditions resulting from the activity of the polypeptides. Compound screening assays can also be based upon the ability of test
10 compounds to modulate the interaction of the target peptide (HFE2A Polypeptide) and known or discovered interacting proteins or protein receptors. Such interacting proteins can be identified by a variety of methods known in the art, including, for example, radioimmunoprecipitation, co-immunoprecipitation, use of epitope-tagged constructs in pull down
15 experiments, co-purification by extraction and chromatography techniques, and yeast two-hybrid screening. Such interactions can be further assayed by means including but not limited to direct detection methods such as surface plasmon resonance, fluorescence with fluorophores or fluorochromes and quenching with chromophores, radiolabelled proteins, fluorescence
20 polarization, confocal fluorescence imaging or scintillation proximity techniques. Indirect interactions may also be monitored through cell viability assays, second messenger reporting such as, G-protein coupled receptor assays, cAMP detection, nitric oxide synthase, phosphodiesterase activity, or lipid modification such as sphingomyelinase, inositol triphosphate assays.

25 Agents that have the effect of modulating the half-life of HFE2A Polypeptide are also useful for treating diseases of iron metabolism. By way of non-limiting example, an assay for this kind of agent comprises cells expressing a wild-type HFE2A Polypeptide wherein such polypeptides are transiently metabolically labeled during translation, contacted with a candidate
30 compound, and the half-life of the polypeptide is determined using standard techniques. Compounds that modulate the half-life of the polypeptide are useful compounds in the present invention.

In one such assay for which the polypeptides encoded by genes disclosed herein are useful, the purified or semi-purified HFE2A polypeptide (or a fragment thereof or an epitope-tagged form or fragment thereof) is bound to a suitable support (e.g., nitrocellulose or an antibody or a metal agarose column in the case of, for example, a his-tagged form of said polypeptide). Binding to the support is preferably done under conditions that allow proteins associated with the polypeptide to remain associated with it. Such conditions may include use of buffers that minimize interference with protein-protein interactions. If desired, other proteins (e.g., a cell lysate) are added, and allowed time to associate with the polypeptide. The immobilized polypeptide is then washed to remove proteins or other cell constituents that may be non-specifically associated with it the polypeptide or the support. The immobilized polypeptide can then be used for multiple purposes. In a compound screening embodiment, such as that provided by Neogenesis Pharmaceuticals, Inc. (Cambridge, MA) the bound HFE2A Polypeptide will be employed in an automated ligand identification system, with low, medium or high-throughput capacity. In this case a pool of test compounds are exposed to HFE2A under conditions (i.e. buffers, temperatures, etc.) which promote specific binding of the test compounds to the protein. Compounds with non-specific binding are separated from the mixture. HFE2A/ligand complexes are then collected, and bound ligands are released and measured by mass spectrometer. A data analysis system correlates mass data with the list of compound masses included in the original test compound mixture. In an alternative embodiment, compounds can be tested for their ability to interfere with interactions between HFE2A Polypeptide and other bound molecules (which are presumably HFE2A Polypeptide interacting proteins). Compounds which can successfully displace interacting proteins are thereby identified as HFE2A Polypeptide modulating agents of the invention. Other well known protein binding assays, which use purified or semi-purified target protein, can also be employed to identify test compounds with specific binding affinity for the protein.

In an alternative embodiment designed to identify HFE2A Polypeptide interacting proteins, the immobilized polypeptide is dissociated from its support, and proteins bound to it are released (for example, by heating), or, alternatively, associated proteins are released from the polypeptide without releasing the latter polypeptide from the support. The released proteins and other cell constituents can be analyzed, for example, by SDS-PAGE gel electrophoresis, Western blotting and detection with specific antibodies, phospho-amino acid analysis, protease digestion, protein sequencing, or isoelectric focusing. Normal and mutant forms of such polypeptide can be employed in these assays to gain additional information about which part of the polypeptide a given factor is binding to. In addition, when incompletely purified polypeptide is employed, comparison of the normal and mutant forms of the protein can be used to help distinguish true binding proteins. Such an assay can be performed using a purified or semipurified protein or other molecule that is known to interact with a polypeptide encoded by an HFE2A polynucleotide.

This assay may include the following steps.

1. Harvest the encoded polypeptide and couple a suitable fluorescent label to it;
2. Label an interacting protein (or other molecule) with a second, different fluorescent label. Use dyes that will produce different quenching patterns when they are in close proximity to each other versus when they are physically separate (i.e., dyes that quench each other when they are close together but fluoresce when they are not in close proximity);
3. Expose the interacting molecule to the immobilized polypeptide in the presence or absence of a compound being tested for its ability to interfere with an interaction between the two; and
4. Collect fluorescent readout data.

An alternative assay for such protein interaction is the Fluorescent Resonance Energy Transfer (FRET) assay. This assay can be performed as follows.

1. Provide the encoded protein or a suitable polypeptide fragment thereof and couple a suitable FRET donor (e.g., nitro-benzoxadiazole (NBD)) to it;
2. Label an interacting protein (or other molecule) with a FRET acceptor (e.g., rhodamine);
3. Expose the acceptor-labeled interacting molecule to the donor-labeled polypeptide in the presence or absence of a compound being tested for its ability to interfere with an interaction between the two; and
4. Measure fluorescence resonance energy transfer.

Quenching and FRET assays are related. Either one can be applied in a given case, depending on which pair of fluorophores is used in the assay.

The description of the HFE2A provided herein teaches a wide variety of biological activities of HFE2A that may be useful for the development of low, medium or high-throughput screening assays.

One useful biological activity that works for a variety of assays is ligand binding (i.e. assays which either inhibit or enhance HFE2A binding with a ligand). The hepcidin protein (OMIM: 606464; See Roetto, A. et al. 2003. *Nature Genet.* 33: 21-22) may be a ligand of HFE2A. Those skilled in the art may find other ligands. Assays based on whole cells, cell extracts or purified proteins may be developed which measure the capacity of a test compound to inhibit or enhance HFE2A binding with a specific ligand.

Cell function assays can be designed. In these assays, a measurable cell function which is dependent on HFE2A activity can be measured to determine inhibition or enhancement by test compounds. Such functions include cell growth assays, such as where compounds are evaluated for their ability to influence axonal growth, in assays such as those described in PCT patent publication WO 02/051438, incorporated herein by reference in its entirety. Based on the presence of RGD and von Willibrand factor-like domains, HFE2A may be involved in cell-cell adhesion. An assay can be

designed which relies on the biological activity of HFE2A induced adhesion, and measures a test compound's ability to modulate adhesion.

In other cell based assays, an HFE2A protein response is first calibrated. For example HFE2A may modulate release of iron by
5 macrophages to transferrin. Or, HFE2A may modulate transport of iron across a CaCo2 membrane. Alternatively, HFE2A may induce a change in NRAMP2 iron transport behavior in an assay. One may assay for compounds which modulate these induced responses to HFE2A and thereby find a modulator of a biological activity of HFE2A. Signaling assays can be developed based on
10 possible functions of HFE2A as a signaling molecule. Iron transport assays that may be adapted include iron uptake in an HFE-CHO cell model for duodenal crypt cells. This can be adapted to assay in 96-well plates wherein test compounds will reduce iron uptake. Similarly, test compounds may inhibit 59Fe-bound transferrin uptake in human hepatoma cells (HLF). Assays that
15 may be suitable for adaptation include those described in Su, M.A. et al. Blood, Vol. 92 No. 6 (September 15), 1998: pp. 2157-2163; Nunez MT, et al. J Nutr 1996 Sep;126(9):2151-8; Tandy S, et al. J Biol Chem 2000 Jan 14;275(2):1023-9; or Feeney GP and Worwood M. Biochim Biophys Acta 2001 Apr 23;1538(2-3):242-51). HFE2A shares sequence similarity and
20 similar structural domains with the human repulsive guidance molecule (RGM), (fig.3) and to chicken RGM-like molecule (fig5). RGMs are a family of proteins involved in neural development and immune response (see WO 02/051438), though assignment of at least some of these functions to HFE2A protein must be considered doubtful, as protein and mRNA expression is not
25 found in neural cells. In any case, related proteins are known to act locally on the cell membrane as receptors, initiating intracellular signals, and systemically as a cleaved soluble protein. Like the chicken RGM, HFE2A has a putative extracellular cleavage site suggesting that it acts as a soluble peptide. One proposed mechanism of action could be that this secreted
30 molecule interacts with proteins on the basal-lateral surface of the intestinal epithelial cells, like hepcidin, and modulates the apical surface uptake of iron from diet. This interaction could be direct, at the basal surface of the intestinal

cells, or via an upstream interaction resulting in modulating iron uptake. This direct or indirect effect can be assayed in a cell culture system.

An example of a compound screening assay which relies on an HFE2A induced response (i.e. an HFE2A biological activity) is a Caco2 HFE2A induced iron transport assay. Caco2 cells are a human colorectal carcinoma cell line and considered the standard for measuring intestinal absorption. These cells grown to confluence form distinct apical and basalateral surfaces and tight junctions. Grown on permeable membranes in Transwell plate inserts, Caco2 cells become polarized with the basalateral surface of the cell on the membrane and exposed to the B chamber solutes, while the apical side of the cell is exposed to solutes in the A chamber. This system is useful to measure active transport of iron through the intestinal epithelium from A to B, mimicking transport from the intestinal lumen through the cell to the blood. A response to HFE2A can be induced by adding HFE2A to the B (basolateral) chamber of the CaCo2 assay. Recombinant HFE2A can be produced in mammalian cells and the purified protein directly added to the B chamber. Alternatively, cultured cells can be transfected with HFE2A constructs and then express HFE2A protein. Appropriate cells for transfection would be HepG2 or RAW cells, human liver carcinoma cells or mouse macrophage cells, respectively. These two cell types are known to be involved in iron metabolism, and likely express HFE2A. The media from these transfected "donor" cells containing HFE2A can now be applied to the B chamber of the Caco2 cells, "acceptor" of the conditioned media, and iron absorption from the A chamber can be monitored. The transfected donor cells could also be grown on the bottom of the B chamber surface, thus directly releasing HFE2A into the B chamber, within millimeters from the basal surface of the acceptor cells.

Whether HF2A acts as a receptor, intracellular signal molecule or secreted protein, this multicellular communication system can be applied to measure an HFE2A induced response. The assay may measure iron transport, iron uptake from the A chamber, iron absorption and/or cell secretion of iron to the B chamber. This cell communication system can

thereafter be applied to primary drug compound screening for iron modulation in intestinal absorption.

Using whole cells or cell extracts, assays can be developed for compounds which increase or decrease GPI cleavage or secretion of HFE2A or for compounds which increase or decrease N-glycosylation of HFE2A. Assays that measure compounds which modulate post-translational modifiers of HFE2A can be used to identify potential therapeutic agents.

Some assays preferably employ purified or semi-purified HFE2A protein assays. This protein may be the GPI-linked form, or the cleaved, soluble form. 125 I labelled HFE2A may be useful for these assays. Such assays include aggregation, assays which are designed based on the tendency of HFE2A to aggregate or homodimerize via the RGD or von Willibrand factor-like domains. In this assay, compounds are tested for their ability to enhance or prevent aggregation of homophilic dimerization domains. In this case, the protein-protein interaction assays above can use two pools of HFE2A, each labelled with a different fluorophore. In some embodiments a GPI-cleaved form of HFE2A may be used with the GPI-linked form. An alternate semi-purified format includes yeast 2-hybrid and/or phage display formats, wherein HFE2A binding regions are incorporated into both bait and prey vectors. This format would provide a moderately high throughput screening assay, suitable for radioimmunoassay or plate format..

In addition it is to be noted that HFE2A may interact with other known proteins of the iron metabolic pathway: Transferrin, Tf receptor, Hfe, hepcidin, p97 or other iron transporters, and receptors thereof. This interaction is a useful activity which may be used as the basis for a screening assay.

Additionally, drug screening assays can also be based upon polypeptide functions deduced upon antisense interference with the gene function. Intracellular localization of HFE2A, or effects which occur upon a change in intracellular localization of such proteins, can also be used as an assay for drug screening.

In accordance with the foregoing, the present invention provides the amino acid sequence of a protein, designated hemojuvelin or HFE2A, that is found in tissues of the human body (for example, SEQ ID NO: 10 - 12 from humans) and which is associated with hereditary transmission of juvenile hemochromatosis. In addition, several mutations, have been found in this sequence derived from individuals found to have juvenile hemochromatosis. Thus, agents that interact with hemojuvelin or HFE2A represent candidate compounds for evaluation as therapeutic agents of the invention.

Another broad category of screening assays is transcription assays. These assays seek to identify compounds which modulate (i.e. increase or decrease) transcription of the HFE2A gene. Relating to transcription assays, in one aspect the present invention relates to a method for identifying an agent that modulates the activity of a polynucleotide whose transcription contributes to amelioration of a disease of iron metabolism, comprising:

- a) contacting under physiological conditions a chemical agent with a polynucleotide corresponding to the promoter region of HFE2A (in a preferred embodiment, the promoter has the sequence of SEQ ID NO: 19); and
- b) detecting a change in the transcription of said polynucleotide as a result of said contacting;

thereby identifying an agent that modulates transcription of said polynucleotide or gene activity.

Such modulation is preferably a decrease or an increase in transcription. In preferred embodiments, such transcription is measured by measuring the amount of a transcription product. In a convenient embodiment, the promoter region of HFE2A is operably linked to a reporter gene, that is, a gene whose transcription is conveniently measured (for example, reporter genes such as Green Fluorescent Protein, luciferase, chloramphenicol acetyl-transferase (CAT), and the like).

In preferred embodiments, the polynucleotide whose transcription is to be measured or monitored is present in an intact cell, preferably a mammalian cell, most preferably a cell selected from among macrophages, hepatocytes, intestinal cells, hematopoietic cells, pancreatic cell, skeletal muscle cell and

other cells of the bone marrow, neurological, CNS or spinal cells, although cells from other tissues may also be used. In additional preferred embodiments, such an intact cell is a cell that has been engineered to comprise said polynucleotide, such as by genetic engineering, preferably
5 wherein the cell does not express the subject gene or polynucleotide absent having been engineered to do so. Alternatively, non-recombinant cells can be employed, as for example, in cells of tissues or cell lines where the transcription of HFE2A is constitutive, or can be induced.

In accordance with the disclosure herein, upstream untranslated
10 regions and promoter regions of HFE2A Gene are readily obtained from SEQ ID No. 19 or 22 and other publicly retrievable sequence databases. Such genomic or untranslated regions may be included in plasmids comprising the identified gene, such as in assays to identify compounds which modulate transcription thereof. In one such assay, the upstream genomic region is
15 ligated to a reporter gene, and incorporated into a transcription plasmid. The plasmid is transfected into a cell, and the recombinant cell is exposed to test compound(s). Those compounds which increase or decrease the expression of the reporter gene are then modulators of the gene/protein, and are considered therapeutic agents of the invention.

20 The invention also claims recombinant cells engineered to express a polynucleotide or polypeptide as disclosed herein. The gene disclosed herein as being involved in HFE2A in an animal can be used, or a fragment thereof can be used, as a tool to express a protein, where such genes encode a protein, in an appropriate cell *in vitro*, or can be cloned into expression vectors
25 which can be used to produce large enough amounts of protein to use in *in vitro* assays for drug screening. Alternatively, the expression construct may employ the genomic promoter region of HFE2A and link it to a gene, such as a reporter gene, whose expression level is easily measured. Expression systems which may be employed include baculovirus, herpes virus, adenovirus, adeno-associated virus, bacterial systems, and eucaryotic
30 systems such as CHO cells. Naked DNA and DNA-liposome complexes can

also be used. The invention thus claims recombinant cell lines containing a heterologous HFE2A gene.

Such recombinant cells may be used in transcription assays for analyzing the levels of transcription of HFE2A Gene or a suitable reporter gene after contacting said cells with agents that may have therapeutic properties. The levels of gene transcription can be quantified by Northern blot analysis or RT-PCR, or, alternatively, by measuring the amount of protein produced, by one of a number of methods known in the art, or by measuring the levels of biological activity of polypeptides encoded thereby or other genes. In this way, the gene transcription can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

Recombinant cell lines are also preferred for the preparation of purified protein, if a purified protein assay is desired. Those skilled in the art are capable of producing recombinant cell lines and extracting protein fractions containing highly purified proteins. These samples can be used in a variety of binding assays to identify compounds which interact with the proteins. Compounds that interact are therapeutic agents of the invention, or analogs thereof.

Target selectivity is an important aspect of the development of therapeutic agents. The present invention specifically contemplates the identification of chemical agents, especially small organic molecules, that agonize or antagonize the transcription of HFE2A Gene, as defined herein, or the activity of the HFE2A Polypeptide (such as SEQ ID NO: 10 - 12 from humans) encoded thereby, with high specificity and that have little or no effect on other genes and/or polypeptides.

Thus, in one such preferred embodiment, the methods disclosed herein for identifying an agent that modulates, preferably inhibits, expression of a gene corresponding to HFE2A, preferably having the sequence of SEQ ID NO: 1 - 9 from humans, or on the activity of a polypeptide encoded thereby, comprises first identifying such agent and then testing such agent for effects

on expression or activity of at least one other gene or polypeptide, preferably a gene or polypeptide with important physiological consequences that are preferably not disturbed by therapeutic intervention, and demonstrating little or no effect.

5 In another aspect, the invention provides a method for computationally identifying a compound of the invention. The method involves (a) determining the crystal structure of an active site of a HFE2A Polypeptide protein (i.e. through x-ray crystallography or other techniques); and (b) through computational modeling, identifying a compound which interacts with the
10 active site, thereby identifying a compound, or its analog, as a compound which is useful for modulating the activity of such a polypeptide. This process is sometimes referred to as *in silico* screening. Sophisticated software for testing the probability of test compounds to interact with the target protein, which can test tens of millions of computer generated compounds, is available
15 to those skilled in the art.

Potential therapeutic compounds identified using the methods of the invention are usually tested in animal model systems to confirm the putative efficacy. Thus, in a further aspect, the present invention relates to a method for identifying a therapeutic agent, comprising:

- 20 a) administering to an animal an agent found to have activity using an assay or screening method as disclosed herein, and
b) detecting in said animal a change in iron metabolism due to said administering,
thereby identifying an agent for the treatment a disease of iron
25 metabolism.

Those skilled in the art are aware that typical measurements of iron metabolism that may be modulated in animal models (i.e., as a result of treatment with a potential therapeutic agent) include transferrin saturation, hepcidin levels, radioactive iron uptake in the gut, liver iron content, whole
30 body iron content, anemia indices. Specialized mouse models for study include anemic mice, iron overload mice, hemochromatosis mice (*hfe/hfe*), *Hpx* mice (hypotransferrinemic mouse), and others.

In a further aspect, the present invention relates to a method for treating a condition in an animal afflicted with a disease of iron metabolism comprising administering to said animal an effective amount of an agent first identified by an assay method of the invention. Preferably, said animal is a human patient, such as a patient afflicted with a disease of iron metabolism.

The screening assays of the invention thus simplify the evaluation, identification and development of therapeutic agents for the treatment of diseases of iron metabolism.

The invention also includes antibodies and immuno-reactive substances which target, interact with or bind to hemojuvelin, HFE2A Polypeptide or epitopes thereof. Polypeptides encoded by the polynucleotides disclosed herein can be used as an antigen to raise antibodies, including monoclonal antibodies. Such antibodies will be useful for a wide variety of purposes, including but not limited to, therapeutic agents, functional studies, drug screening assays, and/or diagnostic agents. Monitoring the influence of agents (e.g., small organic compounds) on the expression or biological activity of the HFE2A polypeptides identified according to the invention can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase or decrease gene transcription, protein levels, or biological activity can be monitored in clinical trials of subjects exhibiting symptoms of diseases of iron metabolism due to inadequate gene transcription, protein levels, or biological activity (for example, the individuals studied herein. Alternatively, the effectiveness of an agent determined by a screening assay to modulate transcription of HFE2A Gene, as well as structurally and functionally related genes, including genes with high homology thereto, and including protein levels, or biological activity can be monitored in clinical trials of subjects exhibiting decreased altered gene transcription, protein levels, or biological activity. In such clinical trials, the transcription or activity of the genes or polypeptides disclosed herein and,

preferably, other genes that have been implicated in, for example, iron metabolism, can be used to ascertain the effectiveness of a particular drug.

In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an
5 agonist, antagonist, peptidomimetic, protein, peptide, antibody, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) including the steps of (i) determining that a patient requires treatment for an iron metabolism disease or disorder; (ii) administering an effective amount of an agent identified using one of the screening assays
10 disclosed herein; (iii) ascertaining an improvement in iron metabolism following said administration and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to decrease the expression or activity of gene or encoded polypeptide, i.e., to increase the effectiveness of the agent.

15 Where the patient is non-human, biopsy samples can be taken to show a decrease in gene transcription, such as by measuring levels of protein, mRNA, or genomic DNA post-administration samples and comparing the level of expression or activity of said protein, mRNA, or genomic DNA in the pre-administration sample with that of the corresponding post administration
20 sample or samples, thereby showing the effects of drug administration on one or more of the genes disclosed herein and concomitant reduction in problems with iron metabolism.

Purified or semi-purified HFE2A protein, or fragments thereof, or proteins corresponding to HFE2A, and any biochemically modified versions
25 thereof, are themselves therapeutic agents of the invention. Recombinant or non-recombinant forms of these proteins or fragments can be administered to persons in need thereof for the treatment of disorders, such as diseases of iron metabolism. Those skilled in the art are familiar with techniques for generating such agents, and for determining conditions of administration.

30 Specific compounds which will modulate the gene expression or gene transcript levels in a cell of HFE2A include antisense nucleic acids, ribozymes and other nucleic acid compositions which specifically hybridize with the

HFE2A gene (including exons or introns of such genes, promoters, 3'-tails, and the like). These specific compounds are compounds of the invention, and are useful for treating the diseases discussed previously. Design and manufacturing of such compounds are well known to those skilled in the art.

5 Specific compounds which modulate the activity of HFE2A include antibodies (polyclonal or monoclonal) and modified antibodies or fragments of antibodies which specifically bind to an epitope of said polypeptide. These specific compounds are compounds of the invention, and are useful for treating the diseases previously discussed. Design and manufacturing of such
10 compounds are well known to those skilled in the art. In particular, humanized antibodies tend to be preferred, such as those generated using techniques provided by Abgenix, Inc. (Freemont, CA), Medarex, Inc. (Princeton, NJ), Protein Design Labs, Inc. (Freemont, CA), Genentech (South San Francisco, CA), and others.

15 Specific compounds which modulate the activity of HFE2A in the body include gene therapy vectors comprising all or a part of the HFE2A gene sequence or mutant HFE2A sequence. As is well known to those skilled in the art, gene therapy allows the delivery of HFE2A in an organism to cells where it is taken up and expressed, thus changing the level or amount of HFE2A
20 Polypeptide protein in such cell. These vectors thereby modulate the activity of HFE2A in the body and are useful for the therapeutic indications disclosed herein.

 Specific compounds which modulate the activity of HFE2A in the body include small organic molecules. Such compounds may be naturally
25 occurring, or they may be synthetic. Collections and combinatorial libraries of such compounds are widely available from commercial sources. As know to those skilled in the art, a screening assay, such as the assays disclosed in the instant specification, can be easily adapted to identify therapeutic agents which have the desired HFE2A modulating ability. Agonists, antagonists, or
30 mimetics found to be effective at reducing disorders of iron metabolism may be confirmed as useful in animal models (for example, mice, chimpanzees, etc.). In other embodiments, treatment with a compound of the invention may

be combined with other therapeutic agents to achieve a combined, possibly even synergistic, effect.

Candidate modulators may be purified (or substantially purified) molecules or may be one component of a mixture of compounds (e.g., an extract or supernatant obtained from cells). In a mixed compound assay, gene expression is tested against progressively smaller subsets of the candidate compound pool (e.g., produced by standard purification techniques, such as HPLC or FPLC) until a single compound or minimal compound mixture is demonstrated to modulate gene or protein activity or expression in a manner having therapeutic effects.

Lead Optimization and Analog Development and Selection

In general, novel drugs having therapeutic properties are identified from libraries, possibly large libraries, of both natural product or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, NH) and Aldrich Chemical (Milwaukee, WI). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA). In

addition, natural and synthetically produced libraries are produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

5 De-replication(e.g., taxonomic de-replication, biological de-replication, and chemical de-replication, or any combination thereof) or the elimination of replicates or repeats of materials already known for their therapeutic activities may be employed whenever possible.

When a crude extract is found to have therapeutic activities, further
10 fractionation of the positive lead extract is possible to isolate chemical constituent responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification process is the careful characterization and identification of a chemical entity within the crude extract having such therapeutic activities. The same assays described herein for the
15 detection of activities in mixtures of compounds can be used to purify the active component and to test derivatives thereof. Methods of fractionation and purification of such heterogeneous extracts are known in the art. If desired, compounds shown to be useful agents for the treatment of pathogenicity are chemically modified according to methods known in the art. Compounds
20 identified as being of therapeutic value are subsequently analyzed using any standard animal model of an iron metabolism disorder known in the art.

In general, these screening methods provide a ready means for selecting either natural product extracts or synthetic compounds of interest from a large population (i.e. a chemical library, for example, one produced by
25 combinatorial means) which are further evaluated and condensed to a few active core structures. Multiple analogs of such core structures may be developed and tested to identify those preferred analogs which have improved characteristics as therapeutic agents.

Improved analogs may also include compounds with improved stability,
30 biodistribution, pharmacokinetics or other desirable features for therapeutic agents which are not directly related to modulation of the therapeutic target. In a preferred embodiment, the improved analog of the invention is effectively

delivered, either by physiological means or assisted means, to cells of the body expressing the HFE2A Polypeptide protein. Analog compounds are systematically screened to evaluate whether they modulate the identified biological activity and those that effectively do so are then therapeutic agents, or further analogs thereof, according to the invention.

Therapeutic Agents and Uses Thereof

Those skilled in the art are familiar with the necessary steps for pre-clinical and human clinical trials which are used to establish efficacy and safety of the new chemical entities and compounds first identified by the invention for use in treating the diseases mentioned herein.

Compounds first identified as useful therapeutic agents using one or more of the assays of the invention may be administered with a pharmaceutically-acceptable diluent, carrier, or excipient, in unit dosage form. Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer such compositions to patients. Although oral administration is preferred, any appropriate route of administration may be employed, for example, intravenous, parenteral, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intrathecal, epidural, intracisternal, intraperitoneal, intranasal, or aerosol administration. Therapeutic formulations may be in the form of liquid solutions or suspension; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.

Methods well known in the art for making formulations are found in, for example, Remington: The Science and Practice of Pharmacy, (19th ed.) ed. A.R. Gennaro AR., 1995, Mack Publishing Company, Easton, PA. Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the

release of the compounds. Other potentially useful parenteral delivery systems for agonists of the invention include ethylenevinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or
5 may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

Combination therapies are also contemplated by the inventors. An therapeutic agent identified by one of the screening methods disclosed herein
10 may be administered along with another agent intended to treat a coincident conditions, such as where therapeutic and antitumor agents are given together or contemporaneously.

The present invention also relates to a process that comprises a method for producing a product, such as by generating test data to facilitate
15 identification of such product, comprising identifying an agent according to one of the disclosed processes for identifying such an agent (i.e., the therapeutic agents identified according to the assay procedures disclosed herein) wherein said product is the data collected with respect to said agent as a result of said identification process, or assay, and wherein said data is
20 sufficient to convey the chemical character and/or structure and/or properties of said agent. For example, the present invention specifically contemplates a situation whereby a user of an assay of the invention may use the assay to screen for compounds having the desired enzyme modulating activity and, having identified the compound, then conveys that information (i.e.,
25 information as to structure, dosage, etc) to another user who then utilizes the information to reproduce the agent and administer it for therapeutic or research purposes according to the invention. For example, the user of the assay (user 1) may screen a number of test compounds without knowing the structure or identity of the compounds (such as where a number of code
30 numbers are used the first user is simply given samples labeled with said code numbers) and, after performing the screening process, using one or more assay processes of the present invention, then imparts to a second user

(user 2), verbally or in writing or some equivalent fashion, sufficient information to identify the compounds having a particular modulating activity (for example, the code number with the corresponding results). This transmission of information from user 1 to user 2 is specifically contemplated by the present invention.

In accordance with the foregoing, the present invention relates to a method for producing test data with respect to the modulation of HFE2A gene expression by a compound, comprising:

(a) a genetic construct comprising a reporter gene operably linked to an HFE2A promoter under conditions supporting expression of said reporter gene;

(b) determining a change in expression of said reporter gene as a result of said contacting, wherein said change shows modulation, and

(c) producing test data with respect to the gene modulating activity of said test compound based on a change in expression of the determined genes indicating gene modulating activity.

In another such embodiment, the present invention relates to a method for producing test data with respect to the modulation of an HFE2A polypeptide activity by a compound, comprising:

(a) contacting a test compound with an HFE2A polypeptide and under conditions promoting an activity of said HFE2A polypeptide;

(b) determining a change in activity of said polypeptide as a result of said contacting, wherein said change shows modulation, and

(c) producing test data with respect to the HFE2A polypeptide modulating activity of said test compound based on a change in an HFE2A polypeptide activity indicating modulating activity.

Diagnostics and Pharmacogenomics

In a further embodiment, the invention relates to diagnostic and pharmacogenomic compounds, kits and methods. This aspect relates to analysis HFE2A Gene (HFE2A, hemojuvelin gene) for the diagnosis, including prognosis of onset or severity of onset, of juvenile hemochromatosis, adult

onset hemochromatosis, a disorder of iron metabolism, or in the selection of a therapeutic agent for a patient (i.e. pharmacogenomics). It also relates to the use of HFE2A diagnosis to classify patients having or at risk of having a disease of iron metabolism.

5 For example, nucleic acid analysis can be used to identify the HFE2A mutations disclosed herein, thus confirming the diagnosis of juvenile hemochromatosis.

10 Using the nucleic acid sequences disclosed in this invention, both the wild-type (non-disease associated) sequences (SEQ ID No. 1 - 9) and the disease associated (mutated) sequences (SEQ ID Nos. 14, 16, and 18), those skilled in the art are capable of developing numerous different types of nucleic acid diagnostic methods, compounds and kits. Techniques include DNA sequencing, hybridization probing, single stranded conformational analysis, PCR based techniques such as mismatch amplification, and myriad other well known methods. All such analysis can be performed on a small sample of blood, saliva, urine or other tissue provided by the patient.

15 Alternatively, using the protein sequences disclosed in this invention (SEQ ID No. 10 - 12) protein based analyses such as antibody based assays (Elisa, Radioimmunoassay and the like) can be employed to identify the expression, amount or presence or absence of a normal or mutant HFE2A protein (HFE2A Polypeptide), such as those mutant polypeptides that result from the mutations disclosed herein.

20 Gene transcription, both comparable and absolute, as well as biological activity, and mutational analysis can each serve as a diagnostic tool for a disease of iron metabolism; thus determination of the amount of HFE2A mRNA can be used to diagnose the presence or absence of a mutation correlated with such a disease.

25 Based on the instant invention, those skilled in the art will also be able to develop other biochemical, chemical and diagnostic assays of HFE2A, mutation which are suitable for use with animal tissue samples.

30 A valuable embodiment of the invention will be to use the diagnostic assays to classify patients having or at risk of having a disease of iron

metabolism. There are many risk factors for diseases of iron metabolism, such as enhanced serum ferritin levels, transferrin receptor saturation, or identification of a mutation in a gene for hemochromatosis (i.e. the Hfe gene). Not all of these risk factors lead to the development of a disease of iron metabolism. Using the teaching of the invention, it is now possible to take patients at risk of having a disease of iron metabolism based on a known risk factor and further assessing them for mutations in HFE2A, wherein a mutation in HFE2A (in one or both copies of the gene) indicates a statistically greater chance of developing the disease of iron metabolism. This discovery particularly aids in diagnosis and prognosis of the risk of adult onset hemochromatosis, which correlates only loosely with the known mutations in the Hfe gene.

What follows is an example of the diagnostic benefit of HFE2A in relation to adult onset hemochromatosis. Nucleic acid or protein analysis used to identify HFE2A mutations disclosed herein, could be used to predict onset or severity of adult hemochromatosis. Adult hemochromatosis displays a wide variability in clinical penetrance. In some human subjects homozygous for HFE mutations there is early onset of a severe phenotype, while in other subjects homozygous for HFE mutations, they remain clinically normal. Assessment of HFE2A gene may be informative for which patients will manifest adult disease and which ones will remain relatively symptom free.

A patient was found to be heterozygous for a mutation in the Hfe1 gene at H63D. This mutation is considered a mild mutation which does not always result in onset of hemochromatosis. A second diagnostic test was then performed on the HFE2A gene. It revealed the following homozygous mutation:

Mutation in HFE2a	Type	Sequence
c.569C>A,p.A190D	WT	gtccaaggagCttggcctcta (SEQ ID NO. 31)
	MT	gtccaaggagAttggcctcta (SEQ ID NO. 32)

The patient developed adult onset hemochromatosis. Thus, detection of mutations in HFE2A is useful in identifying and classifying patients at risk of

developing hemochromatosis, because of a known risk factor (such as Hfe1 mutation), and determining which patients will develop the disease.

This invention therefore discloses a method of classifying a patient at risk of developing a disease of iron metabolism, comprising

- 5 a) performing a first assessment for a disease of iron metabolism, and
 b) performing a diagnostic assay on HFE2A,

wherein a finding of mutation in HFE2A classifies said patient as having a statistically higher risk of developing said disease.

Pharmacogenomics deals with clinically significant hereditary variations
10 in the response to drugs due to altered drug disposition and abnormal action in affected persons (Eichelbaum, M., Clin. Exp. Pharmacol. Physiol., 23:983-985, 1996; Linder, M. W., Clin. Chem., 43:254-266, 1997). In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions
15 drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). Altered drug action may occur in a patient having a polymorphism (e.g., an single nucleotide polymorphism or SNP) in promoter, intronic, or exonic sequences of HFE2A Gene. Thus by determining the presence and prevalence of polymorphisms
20 allow for prediction of a patient's response to a particular therapeutic agent.

This pharmacogenomic analysis can lead to the tailoring of drug treatments according to patient genotype, including prediction of side effects upon administration of therapeutic agents, particularly therapeutic agents for treating disorders disclosed in this specification. Pharmacogenomics allows
25 for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual is examined to determine the ability of the individual to respond to a particular agent).

Diagnostics employing a gene or protein corresponding to HFE2A Gene (HFE2A) can also be useful in selecting patients for clinical trials of a potential therapeutic agent. Patients can be stratified according to the DNA or protein sequence of HFE2A Gene and their response to drug treatment can be evaluated. Such stratification can greatly reduce the number of patients required to establish efficacy for a potential therapeutic agent.

The invention thus comprises compounds, reagents and kits which are designed to identify the presence or absence of mutations in the HFE2A gene.

10

Example 1

Identification of the genetic mutation responsible for juvenile hemochromatosis 2A (HFE2A).

3. We have collected ten Greek families including 13 individuals with JHH. Pedigrees of these families are shown in Figures 9a-9d. Of these families (JH3-12), five have been reported previously (JH3-7) (Papanikolaou, G. et al. Linkage to chromosome 1q in Greek families with juvenile hemochromatosis. Blood Cells Mol. Dis. 27, 744-749 (2001)). Only one family, JH7, is known to be consanguineous. We confirmed that the disease is consistent with linkage to 1q21 (HFE2A; OMIM 602390) in the new families by using 25 genotype markers, including six new microsatellite markers identified from genomic sequence. While the Build 31 human genome sequence assembly contains gaps and duplications, we were able to estimate the size of the linkage interval, and define the linkage boundaries and gene content based on existing sequence contigs. Homozygosity mapping in JH7 defined the limits of the candidate region in an ~1.7 Mb interval between markers CA3AL590452 (141595604-141595847 bp) and CA1AL596177 (143293543-143293826 bp). (The primer sequences for each marker are in Table 6).

Homozygosity in this region was also observed in affected individuals from seven families without known consanguinity. We obtained six different Greek haplotypes by constructing haplotypes using an additional 12 markers. Affected individuals from families JH3, 5, 6, 7, 10, 11 and 12 shared alleles for

at least 6 of 7 markers in the linked interval. Affected individuals from JH4 and 8 displayed different homozygous haplotypes.

Table 6.

D No.	Forward Primer	Reverse Primer
CA3AL 590452	cacttgagcccaggaatttg (SEQ ID NO: 55)	gactcactgcagccttgacc (SEQ ID NO: 56)
CA1AL 596177	gtgtgctacaagttgccgaat (SEQ ID NO: 57)	gcttgaaactgggagttgga (SEQ ID NO: 58)
CA1AL 355505	gggaaatggtcccataattcct (SEQ ID NO: 59)	cgccctgccAATATGTTCT (SEQ ID NO: 60)
D1S44	GGTACTTAGCCTCGAAA TGAGA (SEQ ID NO: 61)	GTGTCACACAACTGGTT G GT (SEQ ID NO: 62)

5

Identification of Mutations in HFE2A

Mutations in HFE2A, (LOC148738) ENSG00000168509, transcript ENST00000306561, Ensembl v.12.31.1, November,2002.

We first sequenced one of three coding exons (ENSE00001277351, v.12.31.1) in this gene. Sequencing was initially limited to those probands that probably carried unique haplotypes, from families JH3 and 4. The first mutation identified was in JH4-203, a T to C transition in the 3' exon (c.842T>C, p.I281T). JH4-203 is homozygous for this SNP. Two siblings and one child, all unaffected, are heterozygous for this SNP. This SNP was not present in any other JH probands or family members and not present in 74 European and 74 Greek control chromosomes.

The second genetic variation identified within this exon is a G to T transversion (c.959G>T, p.G320V). This SNP was homozygous in the JH3 proband. The JH3 affected is homozygous for the c.959T allele and one unaffected sib is heterozygous for this SNP. This SNP was not present in 128 European and 37 Greek control chromosomes. After sequencing all family members of the 10 JH families, it was determined that this SNP is homozygous in the affected individuals from families JH5, JH6, JH7, JH10,

and heterozygous in the JH11 proband and both parents of the JH12 proband.

A third variation, a deletion at nucleotide 1079 (c.1079delC, p.C361fsX366) was identified in the homozygous state in the JH8. This results in 5 unique amino acids and a premature stop. This SNP was also present in the JH11 proband, indicating that this individual is a compound heterozygote.

Additional information about the sequences disclosed in the SEQ ID listing in this specification:

10

LOC148738 Exons

Exons 1, 3a, 3b and 4 may also be found at Gene ENSG00000168509 (Ensembl) and REFSEQ NM_145277.1 (NCBI). Exon 2 may be inferred from an ensembl prediction based on the sequence AK098165.1.

To simplify sequence searching, exon sequence coordinates are provided below based on the NCBI 31 assembly of the human genome. The SEQ ID NOs for these are:

SEQ ID NO. 1 - Exon1 ENSE00001155188

Start:142000393, End:142000541 Chr: 1

20

SEQ ID NO. 2 - Exon2

Start: 142001790, End: 142001993 Chr:1

SEQ ID NO. 3 - Exon3a ENSE00001155182

Start: 142002394, End: 142002430 Chr:1

SEQ ID NO. 4 - Exon3b ENSE00001277320

25

Start: 142002394, End: 142002953 Chr: 1

SEQ ID NO. 7 – Transcript 2 ENST00000317920

Exons 1, 3a, 4, translation_start: 208

SEQ ID NO. 8— Transcript 3 Exons 1, 3b, 4 translation_start: 392

SEQ ID NO. 9 – Transcript 4 Exons 1, 2, 3b, 4 translation_start: 257

30

LOC148738 Translated Proteins

Protein1 is the protein translation of Transcript 1 and Transcript 2 and is similar to the Ensembl protein ENSP00000320072 and the NCBI protein NP_660320.1. Protein 2 is the protein translation of Transcript 2 and may be found in the protein translation of AK098165.1. Protein 3 is similar to the predicted Ensembl Protein ENSP00000304614. SEQ ID NOs are as follows:

SEQ ID NO. 10 - Protein1 ENSP00000320072

Translated from Transcript 1 and Transcript 2

SEQ ID NO. 11 – Protein 2 –

Translated from Transcript 3

SEQ ID NO. 12 – Protein 3 ENSP00000304614

Translated from Transcript 4

HFE2A Promoter Sequences for Human, Mouse and Rat

For SEQ ID Nos. 19 – 21, the promoter sequence is deemed to begin 1500 bp 5' of the transcriptional start site.

Human Genomic DNA fragment including HFE2A promoter region and exons have SEQ ID NOs as follows:

SEQ ID NO. 22 - Human Genomic DNA fragment including HFE2A promoter region and exons

SEQ ID NO. 23 – similar to gi|24308189|ref|NP_064596.1| Human RGM

SEQ ID No. 24 – Similar to ENSESTP00000023393 Human HFE2A paralog on chromosome 5, sequence starting from first methionine

SEQ ID NO. 25 – Similar to ENSMUSESTP00000016634 Mouse HFE2A

SEQ ID No. 26 – Similar to gi|21758120|dbj|BAC05248.1| Rat HFE2A annotated as from Homo sapiens but nucleotide sequence identified as from rat

SEQ ID No. 27 – Similar to SINFRUP00000138308 Fugu HFE2A, N-terminus not defined

SEQ ID No. 28 – Similar to gi|22651834|gb|AAM95449.1| Chicken
RGM

- 5 Those skilled in the art will be familiar with numerous variations of the
compositions and methods disclosed above, all of which are encompassed by
the claims further set out below.

WHAT IS CLAIMED IS:

1. A method for identifying an agent that modulates HFE2A gene expression, comprising:
 - 5 (a) contacting a test compound with a genetic construct comprising a reporter gene operably linked to an HFE2A promoter under conditions supporting expression of said reporter gene;
 - (b) determining a change in expression of said reporter gene as a result of said contacting,
 - 10 wherein a change in expression identifies said test compound as an agent that modulates HFE2A gene expression.
2. The method of claim 1 wherein said modulation is an increase in expression of said reporter gene.
3. The method of claim 1 wherein said modulation is a decrease in
15 expression of said reporter gene.
4. The method of claim 1 wherein said HFE2A promoter is a mammalian HFE2A promoter.
5. The method of claim 4 wherein said mammal is a member selected from the group consisting of mouse, rat and human.
- 20 6. The method of claim 1 wherein said promoter has the nucleotide sequence of SEQ ID NO: 19.
7. The method of claim 1 wherein said genetic construct is in a cell.
8. The method of claim 7 wherein said cell is a mammalian cell.
9. The method of claim 7 wherein said cell is a recombinant cell
25 engineered to express said gene and wherein said cell does not express said gene absent said engineering.
10. The method of claim 8 wherein said mammalian cell is a macrophage, inflammatory cell, liver cell, hepatocyte, intestinal cell, hematopoietic cell, pancreatic cell, skeletal muscle cell or a nervous system
30 cell.

11. The method of claim 1 wherein said test compound is useful in controlling iron metabolism.

12. The method of claim 1 wherein said test compound is first identified as an agent that modulates HFE2A gene expression using said method.

5 13. The method of claim 1 wherein said change is determined by measuring a change in an enzyme activity.

14. A method for identifying an agent that modulates HFE2A gene expression, comprising:

10 a) contacting a test compound with a cell expressing an HFE2A gene;
 b) determining a change in expression of said HFE2A gene as a result of said contacting,

 wherein a change in expression identifies said test compound as an agent that modulates HFE2A gene expression.

15 15. A method for identifying an agent that modulates the activity of an HFE2A polypeptide, comprising:

 a) contacting a test compound with an HFE2A polypeptide under conditions supporting an activity of said polypeptide; and
 b) determining a change in said activity of said polypeptide as a result of said contacting,

20 wherein a change in the activity identifies said test compound as an agent that modulates the activity of an HFE2A polypeptide.

16. The method of claim 15 wherein said HFE2A polypeptide is a mammalian HFE2A polypeptide.

25 17. The method of claim 16 wherein said mammal is a member selected from the group consisting of mouse, rat and human.

18. The method of claim 15 wherein said change is a decrease in said activity.

19. The method of claim 15 wherein said change is an increase in said activity.

30 20. The method of claim 15 wherein said polypeptide is part of a cell.

21. The method of claim 20 wherein said cell is a mammalian cell.

22. The method of claim 20 wherein said cell has been engineered to contain said polypeptide.

23. The method of claim 22 wherein said cell was engineered by genetic engineering.

5 24. The method of claim 23 wherein said cell does not contain said polypeptide absent said engineering.

25. The method of claim 20 wherein said cell is a macrophage, inflammatory cell, liver cell, hepatocyte, intestinal cell, hematopoietic cell, pancreatic cell, skeletal muscle cell or a cell of the nervous system.

10 26. The method of claim 15 wherein said HFE2A polypeptide is highly purified.

27. The method of claim 15 wherein said HFE2A polypeptide is a semi-purified polypeptide.

15 28. The method of claim 15 wherein said HFE2A polypeptide is attached to a solid surface.

29. The method of claim 28 wherein said solid surface is a resin.

30. The method of claim 15 wherein said HFE2A polypeptide is part of an extract.

20 31. The method of claim 15 wherein said polypeptide is encoded by a polynucleotide having the sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 and 9.

32. The method of claim 15 wherein said polypeptide comprises an amino acid sequence selected from SEQ ID NO: 10, 11 and 12.

25 33. A method for treating a disorder comprising administering to an animal afflicted therewith a therapeutically effective amount of an HFE2A modulator.

34. The method of claim 33 wherein said HFE2A modulator exhibits modulating activity in a method of claim 1, 14 or 15.

30 35. The method of claim 34 wherein said modulator was first identified as an HFE2A modulator using said method.

36. The method of claim 33 wherein said HFE2A modulator is a member selected from the group consisting of a selective HFE2A agonist, a selective HFE2A antagonist, pharmaceutically acceptable salts thereof, and combinations of these.

5 37. The method of claim 36 wherein said member is in a pharmaceutically acceptable carrier.

38. The method of claim 33 wherein said HFE2A modulator is selected from an antibody, an anti-sense molecule, a ribozyme and a drug-like small organic molecule.

10 39. The method of claim 33 wherein said disorder is a disease of iron metabolism.

40. The method of claim 39 wherein said disease of iron metabolism is a member selected from the group consisting of an iron overload disorder and an iron deficiency disorder.

15 41. The method of claim 39 wherein said disease of iron metabolism is a member selected from the group consisting of hemochromatosis, transfusion iron overload, thalassemia, porphyria, and juvenile hemochromatosis.

20 42. The method of claim 39 wherein said disease of iron metabolism is a member selected from the group consisting of anemia and anemia of chronic disease.

43. The method of claim 39 wherein said disease of iron metabolism is a member selected from Type I diabetes, Type II diabetes and insulin resistance.

25 44. A method for preventing a disorder comprising administering to an animal, at risk of developing said disorder, a therapeutically effective amount of an HFE2A modulator.

45. The method of claim 44 wherein said HFE2A modulator exhibits modulating activity in a method of claim 1, 14 or 15.

30 46. The method of claim 45 wherein said modulator was first identified as an HFE2A modulator using said method.

47. The method of claim 44 wherein said HFE2A modulator is a member selected from the group consisting of a selective HFE2A agonist, a selective HFE2A antagonist, pharmaceutically acceptable salts thereof, and combinations of these.

5 48. The method of claim 47 wherein said member is in a pharmaceutically acceptable carrier.

49. The method of claim 44 wherein said HFE2A modulator is selected from an antibody, an anti-sense molecule, a ribozyme and a drug-like small organic molecule.

10 50. The method of claim 44 wherein said disorder is a disease of iron metabolism.

51. The method of claim 50 wherein said disease of iron metabolism is a member selected from the group consisting of an iron overload disorder and an iron deficiency disorder.

15 52. The method of claim 50 wherein said disease of iron metabolism is a member selected from the group consisting of hemochromatosis, transfusion iron overload, thalassemia, porphyria, and juvenile hemochromatosis.

20 53. The method of claim 50 wherein said disease of iron metabolism is a member selected from the group consisting of anemia and anemia of chronic disease.

54. The method of claim 50 wherein said disease of iron metabolism is a member selected from Type I diabetes, Type II diabetes and insulin resistance.

25 55. A method to diagnose individuals affected by or at risk of developing a disease of iron metabolism comprising determining a mutation or polymorphism in the nucleic acid sequence of the HFE2A gene in said individual wherein said mutation or polymorphism in said gene identifies said individual as being affected by or at risk of developing a disease of iron
30 metabolism.

56. The method of claim 55 wherein said mutation or polymorphism is a mutation or polymorphism of Table 1.

57. A method to diagnose individuals affected by or at risk of developing a disease of iron metabolism comprising determining a mutation or polymorphism in the amino acid sequence of HFE2A polypeptide in said individual wherein a mutation or polymorphism of said HFE2A polypeptide identifies said individual as being affected by or at risk of developing a disease of iron metabolism.

58. A method to diagnose individuals affected by or at risk of developing a disease of iron metabolism comprising determining a decrease in level or amount of an HFE2A polypeptide in said individual wherein said decrease identifies said individual as being affected by or at risk of developing a disease of iron metabolism.

59. The method of claim 55, 56, 57 or 58 wherein said disease of iron metabolism is adult onset hemochromatosis.

60. The method of claim 55, 56, 57 or 58 wherein said disease of iron metabolism is juvenile hemochromatosis.

61. The method of claim 55, 56, 57 or 58 wherein said disease of iron metabolism is selected from Type I diabetes, Type II diabetes and insulin resistance.

62. A method for identifying a compound capable of modulating a HFE2A activity, comprising: (a) contacting a test compound with a cell that expresses HFE2A; and (b) assaying the ability of said test compound to modulate the transcription of a HFE2A nucleic acid or the activity of HFE2A polypeptide, thereby identifying a compound capable of modulating a HFE2A activity.

63. The method of claim 62, wherein the compound is an anti-HFE2A polypeptide antibody.

64. The method of claim 62, wherein the compound is an antisense HFE2A nucleic acid molecule.

65. The method of claim 62, wherein the compound is a HFE2A ribozyme.

66. The method of claim 62, wherein the compound is a small organic molecule.

5 67. An isolated polynucleotide comprising a polynucleotide having a nucleotide sequence with at least 60 percent identity to a sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 19, 20, 21 and 22.

10 68. The isolated polynucleotide of claim 67 wherein said percent identity is at least 70 percent.

69. The isolated polynucleotide of claim 67 wherein said percent identity is at least 78 percent.

70. The isolated polynucleotide of claim 67 wherein said percent identity is at least 90 percent.

15 71. The isolated polynucleotide of claim 67 wherein said percent identity is at least 95 percent.

72. The isolated polynucleotide of claim 67 wherein said percent identity is at least 98 percent.

20 73. The isolated polynucleotide of claim 67 wherein said nucleotide sequence is a member selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 19, 20, 21 and 22.

25 74. An isolated polypeptide comprising a polypeptide having an amino acid sequence with at least 90 percent identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 11, 12, 23, 24, 25, 26, 27 and 28.

75. The isolated polypeptide of claim 74 wherein said percent identity is at least 95 percent.

76. The isolated polypeptide of claim 74 wherein said percent identity is at least 98 percent.

30 77. The isolated polypeptide of claim 74 wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 10, 11, 12, 23, 24, 25, 26, 27 and 28.

78. A cell line comprising a recombinant form of the polynucleotide of claim 67.

79 A cell line comprising a recombinant form of the polypeptide of claim 74.

80. Use of a cell line of claim 78 or 79 in a method for identifying compositions which modulate expression or activity of hemojuvelin.

81. A composition for treating a disease of iron metabolism comprising a therapeutically effective amount of a polypeptide of claim 74 in a pharmaceutically acceptable carrier.

82. A method for treating a disease of iron metabolism comprising administering to a patient in need thereof a therapeutically effective amount of a composition of claim 81 in a pharmaceutically acceptable carrier

83. The method according to claim 82, wherein said disease is juvenile hemochromatosis.

84. A method for producing test data with respect to the modulation of HFE2A gene expression by a compound, comprising:

(a) a genetic construct comprising a reporter gene operably linked to an HFE2A promoter under conditions supporting expression of said reporter gene;

(b) determining a change in expression of said reporter gene as a result of said contacting, wherein said change shows modulation, and

(c) producing test data with respect to the gene modulating activity of said test compound based on a change in expression of the determined genes indicating gene modulating activity.

85. A method for producing test data with respect to the modulation of an HFE2A polypeptide activity by a compound, comprising:


(a) contacting a test compound with an HFE2A polypeptide under conditions promoting an activity of said HFE2A polypeptide;

(b) determining a change in activity of said polypeptide as a result of said contacting, wherein said change shows modulation, and

(c) producing test data with respect to the HFE2A polypeptide modulating activity of said test compound based on a change in an HFE2A polypeptide activity indicating modulating activity.

5

FIGURE 1







FIGURE 2

FIGURE 3

	20	40	60	80	10
Human :	MCIFPGQSPRSGHGSPPTLS	TLLLLCCGHAISQCK	RCNAEYV	SGGGLCHALRSYALC	RTARTCRG :
Mouse :	MC---	QSPSPRHGSPPTLS	TLLLLCGGQAF	SGGGLCHALRSYALC	RTARTCRG :
Rat :	MCIFPGQSPRSGHGSPPTLS	TLLLLCCGHAISQCK	RCNAEYV	SGGGLCHALRSYALC	RTARTCRG :
Fugu :	MCIFPGQSPRSGHGSPPTLS	TLLLLCCGHAISQCK	RCNAEYV	SGGGLCHALRSYALC	RTARTCRG :
Human :	0	120	140	160	180
Mouse :	DLAFHSAVHGIEDLMI	QHNC	SGQPTAP	PPHARG	ALPC
Rat :	DLAFHSAVHGIEDLMI	QHNC	SGQPTAP	PPHARG	ALPC
Fugu :	DLAFHSAVHGIEDLMI	QHNC	SGQPTAP	PPHARG	ALPC
Human :	00	220	240	260	280
Mouse :	LFVQATSSP	PPHARG	ALPC	PPHARG	ALPC
Rat :	LFVQATSSP	PPHARG	ALPC	PPHARG	ALPC
Fugu :	LFVQATSSP	PPHARG	ALPC	PPHARG	ALPC
Human :	300	320	340	360	380
Mouse :	UKVAEDVARAFSAEQDLQ	CVGSCPP	QRLSRH	NRN	QGL
Rat :	UKVAEDVARAFSAEQDLQ	CVGSCPP	QRLSRH	NRN	QGL
Fugu :	UKVAEDVARAFSAEQDLQ	CVGSCPP	QRLSRH	NRN	QGL
Human :	400	420	440	460	480
Mouse :	FPDAGPPLSA	ATCLVPLLS	SAFLVPL	ATCLV	PLLS
Rat :	FPDAGPPLSA	ATCLVPLLS	SAFLVPL	ATCLV	PLLS
Fugu :	FPDAGPPLSA	ATCLVPLLS	SAFLVPL	ATCLV	PLLS

FIGURE 4

FIGURE 5



WO 2004/092405

PCT/CA2004/000522






FIGURE 6A





FIGURE 7A






FIGURE 7B




FIGURE 7C

WO 2004/092405

PCT/CA2004/000522

```

      *           180           *           200           *
LOC148738 : CASFGDPHVRSPH---EHEHTCRVCGAWPLKENDLEVOATSEPMALCA : 46
gnl|CDD|192 : CSVSGDCMYTTFDGRKQTEPENCITYVLAQDCTSEPSKSVILLKQVN---EGG : 48

      220           *           240           *           260
LOC148738 : NATATRKLTIIIEKNMQECIDOKVYQAEVD---NLPVATEDCGSIN : 87
gnl|CDD|192 : DATCTKSVKVELNDIEIELKQDGGKVTVNSQKVSLEPYKTSDCSIR : 93

```

FIGURE 7D

```

      ↓           *
Human      : FGDPHVRSPH----- : 9
Chicken_RGM : FGDPHLRTF----- : 9

```

FIGURE 7E

FIGURE 8A

1 **ATG**GGGGAGCCAGGCCAGTCCCCTAGTCCCAGGTCTCCCATGGCAGTCCCCCAACTCTA
 1 -M--G--E--P--G--Q--S--P--S--P--R--S--S--H--G--S--P--P--T--L--
 61 AGCACTCTCACTCTCCTGCTGCTCCTCTGTGGACATGCTCATTCTCAATGCAAGATCCTC
 21 -S--T--L--T--L--L--L--L--L--C--G--H--A--H--S--Q--C--K--I--L--
 121 CGCTGCAATGCTGAGTACGTATCGTCCACTCTGAGCCTTAGAGGTGGGGGTTTCATCAGGA
 41 -R--C--N--A--E--Y--V--S--S--T--L--S--L--R--G--G--G--S--S--G--
 181 GCACTTCGAGGAGGAGGAGGAGGAGGCCGGGTGGAGGGGTGGGCTCTGGCGGCCTCTGT
 61 -A--L--R--G--G--G--G--G--G--R--G--G--G--V--G--S--G--G--L--C--
 241 CGAGCCCTCCGCTCCTATGCGCTCTGCACTCGGCGCACCGCCCGCACCTGCCGCGGGGAC
 81 -R--A--L--R--S--Y--A--L--C--T--R--R--T--A--R--T--C--R--G--D--
 301 CTCGCCCTCCATTCCGCGGTACATGGCATCGAAGACCTGATGATCCAGCACAACTGCTCC
 101 -L--A--F--H--S--A--V--H--G--I--E--D--L--M--I--Q--H--N--C--S--
 361 CGCCAGGGCCCTACAGCCCCTCCCCCGCCCCGGGGCCCCGCCCTTCCAGGCGCGGGCTCC
 121 -R--Q--G--P--T--A--P--P--P--P--R--G--P--A--L--P--G--A--G--S--
 421 GGCCTCCCTGCCCCGGACCCCTTGTGACTATGAAGGCCGGTTTTCCCGGCTGCATGGTCTGT
 141 -G--L--P--A--P--D--P--C--D--Y--E--G--R--F--S--R--L--H--G--R--
 481 CCCCCGGGGTCTTGCATTGCGCTTCCTTCGGGGACCCCATGTGCGCAGCTTCCACCAT
 161 -P--P--G--F--L--H--C--A--S--F--G--D--P--H--V--R--S--F--H--H--
 541 CACTTTCACACATGCCGTGTCCAAGGAGCTTGGCCTCTACTGGATAATGACTTCTCTTT
 181 -H--F--H--T--C--R--V--Q--G--A--W--P--L--L--D--N--D--F--L--F--
 601 GTCCAAGCCACCAGCTCCCCCATGGCGTTGGGGGCCAACGCTACCGCCACCCGGAAGCTC
 201 -V--Q--A--T--S--S--P--M--A--L--G--A--N--A--T--A--T--R--K--L--
 661 ACCATCATATTTAAGAACATGCAGGAATGCATTGATCAGAAGGTGTATCAGGCTGAGGTG
 221 -T--I--I--F--K--N--M--Q--E--C--I--D--Q--K--V--Y--Q--A--B--V--
 721 GATAATCTTCTGTAGCCTTTGAAGATGGTTCTATCAATGGAGGTGACCGACCTGGGGGA
 241 -D--N--L--P--V--A--F--E--D--G--S--I--N--G--G--D--R--P--G--G--
 781 TCCAGTTTGTGCGATTCAAAC TGCTAACCTGGGAACCATGTGGAGATCCAAGCTGCCTAC
 261 -S--S--L--S--I--Q--T--A--N--P--G--N--H--V--E--I--Q--A--A--Y--
 841 ATTGGCACAACTATAATCATTCCGGCAGACAGCTGGGCAGCTCTCCTTCTCCATCAAGGTA
 281 -I--G--T--T--I--I--I--R--Q--T--A--G--Q--L--S--F--S--I--K--V--
 901 GCAGAGGATGTGGCCATGGCCTTCTCAGCTGAACAGGACCTGCAGCTCTGTGTTGGGGGG
 301 -A--E--D--V--A--M--A--F--S--A--E--Q--D--L--Q--L--C--V--G--G--
 961 TGCCCTCCAAGTCAGCGACTCTCTCGATCAGAGCGCAATCGTCGGGGAGCTATAACCATT
 321 -C--P--P--S--Q--R--L--S--R--S--E--R--N--R--R--G--A--I--T--I--
 1021 GATACTGCCAGACGGCTGTGCAAGGAAGGGCTTCCAGTGGAAGATGCTTACTTCCATTCC
 341 -D--T--A--R--R--L--C--K--E--G--L--P--V--E--D--A--Y--F--H--S--

FIGURE 9

Open circle/square = Unknown (no data)

Crossed circle/square = Unaffected

Filled circle/square = Affected

Grey circle/square = Unknown (ambiguous)

Slash circle/square = Deceased


FIGURE 9A**JH-003**

FIGURE 9B

JH-004




FIGURE 9C




FIGURE 9D

JH8





FIGURE 9E



SEQUENCE LISTING

<110> Xenon Genetics Inc.

<120> Juvenile Hemochromatosis Gene (HFE2A), Expression Products and Uses Thereof

<130> 836-115PCT

<140> N/A

<141> 2004-04-08

<150> 60/461,615

<151> 2003-04-09

<150> 60/462,867

<151> 2003-04-15

<150> 60/488,607

<151> 2003-07-18

<150> 60/498,458

<151> 2003-08-28

<160> 62

<170> PatentIn version 3.0

<210> 1

<211> 149

<212> DNA

<213> Homo sapiens

<400> 1

cttctctggt tccctgacct cagttagaca gcagccggcc tggggacctg ggggagacac	60
ggaggacccc ctggctggag ctgaccaca gtaggggaa tcatggctgg agaattggat	120
agcagagtaa tgtttgacct ctggaaaca	149

<210> 2

<211> 204

<212> DNA

<213> Homo sapiens

<400> 2

ccaaatttct tttttcagtc acttacaggg cttccgggtca aaattcacta ggtaggaggg	60
tcatcagctg ggaagaaccg gcgcctggga aacctggctg gataggatg ggggagccag	120
gccagtcccc tagtcccagg tcctcccatg gcagtcccc aactctaagc actctcactc	180
tcctgctgct cctctgtgga catg	204

<210> 3

<211> 37

<212> DNA

<213> Homo sapiens

<400> 3
ctcattctca atgcaagatc ctccgctgca atgctga 37

<210> 4
<211> 560
<212> DNA
<213> Homo sapiens

<400> 4
ctcattctca atgcaagatc ctccgctgca atgctgagta cgtatcgccc actctgagcc 60
ttagagggtgg ggggttcatca ggagcacttc gaggaggagg aggaggaggc cgggggtggag 120
gggtgggctc tggcgggcctc tgctgagccc tccgctccta tgctctctgc actcggcgca 180
ccgcccgcac ctgcccgggg gacctcgctt gccctacagc ccctcccccg ccccggggccc 240
tgatgatcca gcacaactgc tcccggcagg gccctacagc ccctcccccg ccccggggccc 300
ccgccccttc aggcgcgggg tccggcctcc ctgccccgga cccttgtagc tatgaaggcc 360
gggtttcccg gctgcatggg cgtcccccg gggtcttgca ttgctcttc ttcggggacc 420
cccatgtgcg cagcttccac catcactttc acacatgccg tgtccaagga gcttggcctc 480
tactggataa tgacttctc tttgtccaag ccaccagctc ccccatggcg ttgggggcca 540
acgtaccgc caccggaag 560

<210> 5
<211> 1230
<212> DNA
<213> Homo sapiens

<400> 5
ctcaccatca tatttaagaa catgcaggaa tgcattgac agaagggtga tcaggctgag 60
gtggataatc ttctgttagc ctttgaagat ggttctatca atggagggtga ccgacctggg 120
ggatccagtt tgcgattca aactgctaac cctgggaacc atgtggagat ccaagctgcc 180
tacattggca caactataat cattcggcag acagctgggc agctctcctt ctccatcaag 240
gtagcagagg atgtggccat ggccttctca gctgaacagg acctgcagct ctgtgttggg 300
gggtgccctc caagtcagcg actctctcga tcagagcgca atcgctgggg agctataacc 360
attgatactg ccagacggct gtgcaaggaa gggcttcag tggagatgc ttacttccat 420
tcctgtgtct ttgatgtttt aatttctggg gatcccaact ttaccgtggc agctcaggca 480
gcactggagg atgcccagc cttcctgcca gacttagaga agctgcatct cttcccctca 540
gatgctgggg ttctctcttc ctcagcaacc ctcttagctc cactcctttc tgggctcttt 600
gttctgtggc tttgcattca gtaaggggac catcagctcc attactagtt tggaaatgat 660
ttggagatac agattggcat agaagaatgt aaagaatcat taaaggaagc agggcctagg 720
agacacgtga aacaatgaca ttatccagag tcagatgagg ctgcagtcga gggttgaaat 780
tatcacagaa taaggattct gggcaagggt actgcattcc ggatctctgt ggggctcttc 840
accaattttt ccagcctcat ttatagtaaa caaattgttc taatccattt actgcagatt 900
tcacccttat aagtttagag gtcatgaagg ttttaatgat cagtaaagat ttaagggttg 960
agatttttaa gaggcaagag ctgaaagcag aagacatgat cattagccat aagaaactca 1020
aaggaggaag acataattag ggaaagaagt ctatttgatg aatatgtgtg tgtaagggtat 1080
gttctgcttt cttgattcaa aaatgaagca ggcattgtct agctcttagg tgaaggaggt 1140
ctctgctttt gaagaatggc acaggtagga cagaagtatc atccctacc cctaactaat 1200
ctgttattaa agctacaaat tcttcacacc 1230

<210> 6
<211> 1379
<212> DNA
<213> Homo sapiens

<400> 6

cttctctggt	tccctgacct	cagttagaca	gcagccggcc	tggggacctg	ggggagacac	60
ggaggacccc	ctggctggag	ctgacccaca	gagtagggaa	tcatggctgg	agaattggat	120
agcagagtaa	tggttgacct	ctggaaacac	tcaccatcat	atttaagaac	atgcaggaa	180
gcattgatca	gaaggtgat	caggctgagg	tggataatct	tcctgtagcc	tttgaagatg	240
gttctatcaa	tggaggtgac	cgacctgggg	gatccagttt	gtcgattcaa	actgctaacc	300
ctgggaacca	tgtggagatc	caagctgcct	acattggcac	aactataatc	attcggcaga	360
cagctgggca	gctctccttc	tccatcaagg	tagcagagga	tgtggccatg	gccttctcag	420
ctgaacagga	cctgcagctc	tgtgttgggg	ggtgcctcc	aagtcagcga	ctctctcgat	480
cagagcgcaa	tcgtcgggga	gctataacca	ttgatactgc	cagacggctg	tgcaagggaag	540
ggcttccagt	ggaagatgct	tacttccatt	cctgtgtctt	tgatgtttta	atttctggtg	600
atcccaactt	taccgtggca	gctcaggcag	cactggagga	tgcccagagc	ttcctgccag	660
acttagagaa	gctgcatctc	ttccccctcag	atgctggggg	tcctctttcc	tcagcaaccc	720
tcttagctcc	actcctttct	gggctctttg	ttctgtggct	ttgcattcag	taaggggacc	780
atcagtccca	ttactagttt	ggaaatgatt	tggagataca	gattggcata	gaagaatgta	840
aagaatcatt	aaaggaagca	gggccttagga	gacacgtgaa	acaatgacat	tatccagagt	900
cagatgaggc	tgagtcocag	gggtgaaatt	atcacagaat	aaggattctg	ggcaagggtta	960
ctgcattccg	gatctctgtg	gggctcttca	ccaatttttc	cagcctcatt	tatagtaaac	1020
aaattgttct	aatccattta	ctgcagattt	cacccttata	agtttagagg	tcatgaagggt	1080
tttaatgatc	agtaaagatt	taaggggtga	gatttttaag	aggcaagagc	tgaaagcaga	1140
agacatgatc	attagccata	agaaactcaa	aggaggaaga	cataattagg	gaaagaagtc	1200
tatttgatga	atatgtgtgt	gtaagggtatg	ttctgctttc	ttgattcaaa	aatgaagcag	1260
gcattgtcta	gctcttaggt	gaagggagtc	tctgcttttg	aagaatggca	caggtaggac	1320
agaagtatca	tccctacccc	ctaactaatc	tgttattaaa	gctacaaatt	cttcacacc	1379

<210> 7
 <211> 1416
 <212> DNA
 <213> Homo sapiens

<400> 7						
cttctctggt	tccctgacct	cagttagaca	gcagccggcc	tggggacctg	ggggagacac	60
ggaggacccc	ctggctggag	ctgacccaca	gagtagggaa	tcatggctgg	agaattggat	120
agcagagtaa	tggttgacct	ctggaaacac	tcattctcaa	tgcaagatcc	tccgctgcaa	180
tgctgactca	ccatcatatt	taagaacatg	caggaatgca	ttgatcagaa	gggtgatcag	240
gctgaggtgg	ataatcttcc	tgtagccttt	gaagatgggt	ctatcaatgg	aggtgaccga	300
cctgggggat	ccagtttgte	gattcaaaact	gctaaccctg	ggaaccatgt	ggagatccaa	360
gctgcctaca	ttggcacaac	tataatcatt	cggcagacag	ctgggcagct	ctccttctcc	420
atcaaggtag	cagaggatgt	ggccatggcc	ttctcagctg	aacaggacct	gcagctctgt	480
gttggggggg	gccctccaag	tcagcgactc	tctcgatcag	agcgcaatcg	tcggggagct	540
ataaccattg	atactgccag	acggctgtgc	aaggaagggc	ttccagtggg	agatgcttac	600
ttccattcct	gtgtctttga	tgttttaatt	tctgggtgatc	ccaactttac	cgtggcagct	660
caggcagcac	tggaggatgc	ccgagccttc	ctgccagact	tagagaagct	gcattctctc	720
cctcagatg	ctgggggttcc	tctttcctca	gcaaccctct	tagctccact	cctttctggg	780
ctctttgttc	tgtggctttg	cattcagtaa	ggggaccatc	agtccatta	ctagtttgga	840
aatgatttgg	agatacagat	tggcatagaa	gaatgtaaag	aatcattaaa	ggaagcaggg	900
cctaggagac	acgtgaaaca	atgacattat	ccagagttag	atgaggctgc	agtccagggt	960
tgaaattatc	acagaataag	gattctgggc	aaggttactg	cattccggat	ctctgtgggg	1020
ctcttcacca	atttttccag	cctcatttat	agtaaacaaa	ttgttcta	ccatttactg	1080
cagatttca	ccttataagt	ttagaggtca	tgaaggtttt	aatgatcagt	aaagatttaa	1140
gggttagagt	ttttaagagg	caagagctga	aagcagaaga	catgatcatt	agccataaga	1200
aactcaaagg	aggaagacat	aattagggaa	agaagtctat	ttgatgaata	tgtgtgtgta	1260
aggtatgttc	tgttttcttg	attcaaaaa	gaagcaggca	ttgtctagct	cttaggtgaa	1320
gggagtctct	gcttttgaag	aatggcacag	gtaggacaga	agtatcatcc	ctacccccta	1380
actaatctgt	tattaaagct	acaaattctt	cacacc			1416

<210> 8
 <211> 1939
 <212> DNA
 <213> Homo sapiens

<400> 8
 cttctctggt tccctgacct cagttagaca gcagccggcc tggggacctg ggggagacac 60
 ggaggacccc ctggctggag ctgacccaca gaggtaggaa tcatggctgg agaattggat 120
 agcagagtaa tgtttgacct ctggaaacac tcattctcaa tgcaagatcc tccgctgcaa 180
 tgctgagtac gtatcgtcca ctctgagcct tagaggtggg ggttcatcag gagcacttcg 240
 aggaggagga ggaggaggcc ggggtggagg ggtgggctct ggcggcctct gtcgagccct 300
 ccgctcctat gcgctctgca ctggcgccac cgcccgacc tgccgcgggg acctcgccct 360
 ccattcggcg gtacatggca tcgaagacct gatgatccag cacaactgct ccgcgcaggg 420
 ccctacagcc cctccccgcg cccggggccc cgcccttcca ggcgcggggt ccggcctccc 480
 tgccccggac ccttgtgact atgaaggccg gttttcccg ctgcatggtc gtccccggg 540
 gttcttgcat tgcgcttcct tcggggaccc ccatgtgcgc agcttccacc atcactttca 600
 cacatgcogt gtcgaaggag cttggcctct actggataat gacttccctt ttgtccaagc 660
 caccagctcc cccatggcgt tgggggccc aa cgctaccgcc acccggaagc tcaccatcat 720
 atttaagaac atgcaggaat gcattgatca gaaggtgtat caggctgagg tggataatct 780
 tctgttagcc tttgaagatg gttctatcaa tggaggtgac cgacctgggg gatccagttt 840
 gtcgattcaa actgctaacc ctgggaacca tgtggagatc caagctgcct acattggcac 900
 aactataatc attcggcaga cagctgggca gctctccttc tccatcaagg tagcagagga 960
 tgtggccatg gccttctcag ctgaacagga cctgcagctc tgtgttgggg ggtgccctcc 1020
 aagtcagcga cctctctgat cagagcgcaa tcgtcgggga gctataacca ttgatactgc 1080
 cagacggctg tgcaaggaag ggcttccagt ggaagatgct tacttccatt cctgtgtctt 1140
 tgatgtttta atttctggtg atcccaactt taccgtggca gctcaggcag cactggagga 1200
 tgccccagcc ttcttgccag acttagagaa gctgcatctc ttccctcag atgctggggg 1260
 tctcttttcc tcagcaacct tcttagctcc actccttctt gggctctttg ttctgtggct 1320
 ttgcattcag taaggggacc atcagtccca ttactagttt ggaaatgatt tggagataca 1380
 gattggcata gaagaatgta aagaatcatt aaaggaagca gggcctagga gacacgtgaa 1440
 acaatgacat tatccagagt cagatgaggc tgcagtcag ggttgaaatt atcacagaat 1500
 aaggattctg ggcaaggcta ctgcattccg gatctctgtg gggctcttca ccaatttttc 1560
 cagcctcatt tatagtaaac aaattgttct aatccattta ctgcagattt cacccttata 1620
 agtttagagg tcattgaagg tttaatgatc agtaaagatt taagggttga gatttttaag 1680
 aggcaagagc tgaaagcaga agacatgatc attagccata agaaactcaa aggaggaaga 1740
 cataattagg gaaagaagtc tatttgatga atatgtgtgt gtaaggtagt ttctgcttcc 1800
 ttgattcaaa aatgaagcag gcattgtcta gctcttaggt gaagggaagtc tctgcttttg 1860
 aagaatggca caggtaggac agaagtatca tccctacccc ctaactaatc tgttattaaa 1920
 gctacaaaatt cttcacacc 1939

<210> 9
 <211> 2143
 <212> DNA
 <213> Homo sapiens

<400> 9
 cttctctggt tccctgacct cagttagaca gcagccggcc tggggacctg ggggagacac 60
 ggaggacccc ctggctggag ctgacccaca gaggtaggaa tcatggctgg agaattggat 120
 agcagagtaa tgtttgacct ctggaaacac caaatttctt ttttcagtca cttacagggc 180
 ttccggtcaa aattcactag gtaggagggt catcagctgg gaagaaccgg cgcctgggaa 240
 acctggctgg ataggtatgg gggagccagg ccagtcacct agtcccagg cctcccatgg 300
 cagtccccca actctaagca ctctcactct cctgctgctc ctctgtggac atgctcattc 360
 tcaatgcaag atcctccgct gcaatgctga gtacgtatcg tccactctga gccttagagg 420
 tgggggttca tcaggagcac ttcgaggagg aggaggagga ggccgggggtg gaggggtggg 480

```

ctctggcggc ctctgtcgag cctccgctc ctatgcgctc tgcactcggc gcaccgcccg 540
cacctgccgc ggggacctcg cctccattc ggcgggtacat ggcatcgaag acctgatgat 600
ccagcacaac tgctcccgcc agggccctac agccccctcc ccgccccggg gccccgccct 660
tccaggcgcg ggctccggcc tccctgcccc ggacccttgt gactatgaag gccgggtttc 720
ccggctgcat ggtcgtcccc cgggggttctt gcattgcgct tccttcgggg acccccatgt 780
gcgcagcttc caccatcact ttcacacatg ccgtgtccaa ggagcttggc ctctactgga 840
taatgacttc ctctttgtcc aagccaccag ctcccccatg gcgttggggg ccaacgctac 900
cgccaccggg aagctcacca tcatatttaa gaacatgcag gaatgcattg atcagaagg 960
gtatcaggct gaggtggata atcttcctgt agcctttgaa gatggttcta tcaatggagg 1020
tgaccgacct gggggatcca gtttgtcgat tcaaactgct aaccctggga accatgtgga 1080
gatccaagct gcctacattg gcacaactat aatcattcgg cagacagctg ggcagctctc 1140
cttctccatc aaggtagcag aggatgtggc catggccttc tcagctgaac aggacctgca 1200
gctctgtgtt ggggggtgcc ctccaagtca gcgactctct cgatcagagc gcaatcgctc 1260
gggagctata accattgata ctgccagacg gctgtgcaag gaagggttc cagtggaaga 1320
tgcttacttc cattcctgtg tctttgatgt tttatttctt ggtgatccca actttaccgt 1380
ggcagctcag gcagcactgg aggatgccc agccttcctg ccagacttag agaagctgca 1440
tctctcccc tcagatgctg gggttcctct tctctcagca accctcttag ctccactcct 1500
ttctgggctc tttgttctgt ggctttgcat tcagtaaggg gaccatcagt cccattacta 1560
gtttggaat gatttggaga tacagattgg catagaagaa tgtaaagaat cattaagga 1620
agcagggcct aggagacacg tgaaacaatg acattatcca gagtcagatg aggctgcagt 1680
ccagggttga aattatcaca gaataaggat tctgggcaag gttactgcat tccggatctc 1740
tgtggggctc ttcaccaatt tttccagcct catttatagt aaacaaattg ttctaatacca 1800
tttactgcag atttcaccct tataagttta gaggtcatga aggttttaat gatcagtaaa 1860
gatttaaggg ttgagatttt taagaggcaa gagctgaaag cagaagacat gatcattagc 1920
cataagaaac tcaaaggagg aagacataat tagggaaaga agtctatttg atgaatatgt 1980
gtgtgtaagg tatgttctgc tttcttgatt caaaaatgaa gcaggcattg tctagctctt 2040
aggtgaaggg agtctctgct tttgaagaat ggcacaggta ggacagaagt atcatcccta 2100
ccccctaact aatctgttat taaagctaca aattcttcac acc 2143

```

<210> 10
 <211> 200
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Gln Glu Cys Ile Asp Gln Lys Val Tyr Gln Ala Glu Val Asp Asn
 1 5 10 15
 Leu Pro Val Ala Phe Glu Asp Gly Ser Ile Asn Gly Gly Asp Arg Pro
 20 25 30
 Gly Gly Ser Ser Leu Ser Ile Gln Thr Ala Asn Pro Gly Asn His Val
 35 40 45
 Glu Ile Gln Ala Ala Tyr Ile Gly Thr Thr Ile Ile Ile Arg Gln Thr
 50 55 60
 Ala Gly Gln Leu Ser Phe Ser Ile Lys Val Ala Glu Asp Val Ala Met
 65 70 75 80
 Ala Phe Ser Ala Glu Gln Asp Leu Gln Leu Cys Val Gly Gly Cys Pro
 85 90 95
 Pro Ser Gln Arg Leu Ser Arg Ser Glu Arg Asn Arg Arg Gly Ala Ile
 100 105 110

Thr Ile Asp Thr Ala Arg Arg Leu Cys Lys Glu Gly Leu Pro Val Glu
 115 120 125
 Asp Ala Tyr Phe His Ser Cys Val Phe Asp Val Leu Ile Ser Gly Asp
 130 135 140
 Pro Asn Phe Thr Val Ala Ala Gln Ala Ala Leu Glu Asp Ala Arg Ala
 145 150 155 160
 Phe Leu Pro Asp Leu Glu Lys Leu His Leu Phe Pro Ser Asp Ala Gly
 165 170 175
 Val Pro Leu Ser Ser Ala Thr Leu Leu Ala Pro Leu Leu Ser Gly Leu
 180 185 190
 Phe Val Leu Trp Leu Cys Ile Gln
 195 200

<210> 11
 <211> 313
 <212> PRT
 <213> Homo sapiens

<400> 11
 Met Ile Gln His Asn Cys Ser Arg Gln Gly Pro Thr Ala Pro Pro Pro
 1 5 10 15
 Pro Arg Gly Pro Ala Leu Pro Gly Ala Gly Ser Gly Leu Pro Ala Pro
 20 25 30
 Asp Pro Cys Asp Tyr Glu Gly Arg Phe Ser Arg Leu His Gly Arg Pro
 35 40 45
 Pro Gly Phe Leu His Cys Ala Ser Phe Gly Asp Pro His Val Arg Ser
 50 55 60
 Phe His His His Phe His Thr Cys Arg Val Gln Gly Ala Trp Pro Leu
 65 70 75 80
 Leu Asp Asn Asp Phe Leu Phe Val Gln Ala Thr Ser Ser Pro Met Ala
 85 90 95
 Leu Gly Ala Asn Ala Thr Ala Thr Arg Lys Leu Thr Ile Ile Phe Lys
 100 105 110
 Asn Met Gln Glu Cys Ile Asp Gln Lys Val Tyr Gln Ala Glu Val Asp
 115 120 125
 Asn Leu Pro Val Ala Phe Glu Asp Gly Ser Ile Asn Gly Gly Asp Arg
 130 135 140
 Pro Gly Gly Ser Ser Leu Ser Ile Gln Thr Ala Asn Pro Gly Asn His
 145 150 155 160

Val Glu Ile Gln Ala Ala Tyr Ile Gly Thr Thr Ile Ile Ile Arg Gln
 165 170 175
 Thr Ala Gly Gln Leu Ser Phe Ser Ile Lys Val Ala Glu Asp Val Ala
 180 185 190
 Met Ala Phe Ser Ala Glu Gln Asp Leu Gln Leu Cys Val Gly Gly Cys
 195 200 205
 Pro Pro Ser Gln Arg Leu Ser Arg Ser Glu Arg Asn Arg Arg Gly Ala
 210 215 220
 Ile Thr Ile Asp Thr Ala Arg Arg Leu Cys Lys Glu Gly Leu Pro Val
 225 230 235 240
 Glu Asp Ala Tyr Phe His Ser Cys Val Phe Asp Val Leu Ile Ser Gly
 245 250 255
 Asp Pro Asn Phe Thr Val Ala Ala Gln Ala Ala Leu Glu Asp Ala Arg
 260 265 270
 Ala Phe Leu Pro Asp Leu Glu Lys Leu His Leu Phe Pro Ser Asp Ala
 275 280 285
 Gly Val Pro Leu Ser Ser Ala Thr Leu Leu Ala Pro Leu Leu Ser Gly
 290 295 300
 Leu Phe Val Leu Trp Leu Cys Ile Gln
 305 310

<210> 12
 <211> 426
 <212> PRT
 <213> Homo sapiens

<400> 12
 Met Gly Glu Pro Gly Gln Ser Pro Ser Pro Arg Ser Ser His Gly Ser
 1 5 10 15
 Pro Pro Thr Leu Ser Thr Leu Thr Leu Leu Leu Leu Leu Cys Gly His
 20 25 30
 Ala His Ser Gln Cys Lys Ile Leu Arg Cys Asn Ala Glu Tyr Val Ser
 35 40 45
 Ser Thr Leu Ser Leu Arg Gly Gly Gly Ser Ser Gly Ala Leu Arg Gly
 50 55 60
 Gly Gly Gly Gly Gly Arg Gly Gly Gly Val Gly Ser Gly Gly Leu Cys
 65 70 75 80
 Arg Ala Leu Arg Ser Tyr Ala Leu Cys Thr Arg Arg Thr Ala Arg Thr
 85 90 95
 Cys Arg Gly Asp Leu Ala Phe His Ser Ala Val His Gly Ile Glu Asp
 100 105 110

Leu Met Ile Gln His Asn Cys Ser Arg Gln Gly Pro Thr Ala Pro Pro
 115 120 125
 Pro Pro Arg Gly Pro Ala Leu Pro Gly Ala Gly Ser Gly Leu Pro Ala
 130 135 140
 Pro Asp Pro Cys Asp Tyr Glu Gly Arg Phe Ser Arg Leu His Gly Arg
 145 150 155 160
 Pro Pro Gly Phe Leu His Cys Ala Ser Phe Gly Asp Pro His Val Arg
 165 170 175
 Ser Phe His His His Phe His Thr Cys Arg Val Gln Gly Ala Trp Pro
 180 185 190
 Leu Leu Asp Asn Asp Phe Leu Phe Val Gln Ala Thr Ser Ser Pro Met
 195 200 205
 Ala Leu Gly Ala Asn Ala Thr Ala Thr Arg Lys Leu Thr Ile Ile Phe
 210 215 220
 Lys Asn Met Gln Glu Cys Ile Asp Gln Lys Val Tyr Gln Ala Glu Val
 225 230 235 240
 Asp Asn Leu Pro Val Ala Phe Glu Asp Gly Ser Ile Asn Gly Gly Asp
 245 250 255
 Arg Pro Gly Gly Ser Ser Leu Ser Ile Gln Thr Ala Asn Pro Gly Asn
 260 265 270
 His Val Glu Ile Gln Ala Ala Tyr Ile Gly Thr Thr Ile Ile Ile Arg
 275 280 285
 Gln Thr Ala Gly Gln Leu Ser Phe Ser Ile Lys Val Ala Glu Asp Val
 290 295 300
 Ala Met Ala Phe Ser Ala Glu Gln Asp Leu Gln Leu Cys Val Gly Gly
 305 310 315 320
 Cys Pro Pro Ser Gln Arg Leu Ser Arg Ser Glu Arg Asn Arg Arg Gly
 325 330 335
 Ala Ile Thr Ile Asp Thr Ala Arg Arg Leu Cys Lys Glu Gly Leu Pro
 340 345 350
 Val Glu Asp Ala Tyr Phe His Ser Cys Val Phe Asp Val Leu Ile Ser
 355 360 365
 Gly Asp Pro Asn Phe Thr Val Ala Ala Gln Ala Ala Leu Glu Asp Ala
 370 375 380
 Arg Ala Phe Leu Pro Asp Leu Glu Lys Leu His Leu Phe Pro Ser Asp
 385 390 395 400
 Ala Gly Val Pro Leu Ser Ser Ala Thr Leu Leu Ala Pro Leu Leu Ser

9

405

410

415

Gly Leu Phe Val Leu Trp Leu Cys Ile Gln
420 425

<210> 13
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Polynucleotide replication primer

<400> 13
gctgcctaca ttggcacaac t

21

<210> 14
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Polynucleotide replication primer

<400> 14
gctgcctaca ctggcacaac t

21

<210> 15
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Polynucleotide replication primer

<400> 15
tgtgttgggg ggtgccctcc a

21

<210> 16
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Polynucleotide replication primer

<400> 16
tgtgttgggg tgtgccctcc a

21

<210> 17
<211> 21

<212> DNA
<213> Artificial

<220>
<223> Polynucleotide replication primer

<400> 17
tacttccatt cctgtgtctt t

21

<210> 18
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Polynucleotide replication primer

<400> 18
tacttccatt ctgtgtcttt

20

<210> 19
<211> 1919
<212> DNA
<213> Homo sapiens

<400> 19
tctatataga tattaataaaa tctagagaga cagaaagcag actggtgatg gccagtctag 60
atggctagat agatagacat ggatatagat atagatctct atatagatag aggtagatac 120
agatatagat atatgcccta ttagttctgt tcctctagag aaccctaata cagtgaccgt 180
atttgaatc ggctcctctg ttaatttcac ttggcaagta ctaaaagatg atgatctcag 240
atatacctat ggctgcaaaa acatgacatg gctaaatccc ttggttgcag tatctctttt 300
cttttttaag ggggggtgggg gggcggtct cactgttgcc caggctggag tgcaatggcg 360
ttatcatagc tcaactgcagc ctcaaaactcc tgcgctcaag tgaccctcct gcctcagctc 420
ccaaagtgtg gagattttgc aatatttatg gtcacaagat tatgttattc cataaaagta 480
cttttctgag gctaggcatg ttggttcaca cttgtaatcc cagcactctg agaggctgag 540
atggaaggat tcattgaggc aaggagtcca agaccagcct ggtcaacata gtgagacctc 600
atctcggaag gaaggaagga aggagggagg gaggaagga gggagtgaag gaaggaagga 660
aggaaggaag gaaggaagga aggaaggaag gaaggaagga aaagtatat tttgaatctt 720
tttctatttc tccaactctt tctttagaag aattctattt ccattctttc ttcacctctt 780
tgcctttgtt agccttctct ccaagcaaat cgggagcctt tattttttgt gtattcatga 840
gggagaggaa gatgaattgc tgtacaaact aaagtaatga aaatggagta ggtaggagga 900
tagacagctg caaggatctg agctggatag actgaacaaa ccctcatcct aagcaactca 960
cagctcagat ttcttctctg gacagctggc ttttttcgtc cttctgaaat actctgcaaa 1020
gataggagag gggctatgaa ctacctctgc tatggatctt attcaaagtc agctacctcc 1080
tagatactat ctgtagaacc taaatgtaat attcagcata gcagggatga acatggtaaa 1140
tgaaaggat ccaattggcc actgtaattt ttaaaggcca ggagctcaac attattgaaa 1200
atgctggagg gctgcctgga gtaggcagtg accacagagt cacacaagct ggaattggat 1260
atccaacttg tctgtcatat ttctctcctc cctccctgac ttggcactca atactccata 1320
ttctttctaa tctcttaacc ctccccactc ccccaactcc cacaccctac ccccaaccaac 1380
gttctctgaa ttttggactt agctattttt aaaaccgtca actcagtagc cactccctc 1440
cctgctcagc tgtccagtac tctggccagc catatactcc cccttcccc cataccaaac 1500
cttctctggt tccctgacct cagttagaca gcagccggcc tggggacctg ggggagacac 1560
ggaggacccc ctggctggag ctgaccaca gagtagggaa tcatggctgg agaattggat 1620
agcagagtaa tgtttgacct ctggaaacag taagtcaaaa tgaaattgca attcctttaa 1680

taagcttttta	tattgaagtt	agactttttat	aaaattacaa	acacctactt	ggatgtctct	1740
cgtccaaatg	ctgggatctc	tccctaccaa	ggtgccccaa	tctccatttc	tctttctgtc	1800
ttattttctt	ctggcctctg	gcctctagct	ttttgaagtt	taattctctg	tctctctctt	1860
ggcagtcctt	gccctctctt	tacottatta	cctcaagact	cctgatgaag	ttttagaag	1919

<210> 20
 <211> 1020
 <212> DNA
 <213> Mus musculus

<400> 20						
tgtattgacg	aggaggagg	attggtgcac	acactagcgt	aatggaaaag	gtggagatag	60
aatagacagc	tgcagagatc	tgatccggac	agacagaata	aaccctcctc	cgaaacaatt	120
ctgctctcgg	gtttcttctc	cagacagctg	gcctttcggc	ttctgaaata	gttggcggag	180
atgggggagg	gtctctgaac	tacgcctgcc	atccatcttc	aaagccagct	acctctacgt	240
accatgtgtg	gaaactcagt	ggcatcctca	gtaaagagag	gatgagaacg	gtgagtgaca	300
ggcgtcacac	aaatcaccac	cagccgtctt	acaggccggg	agctcattac	tgagaacgct	360
aaaggacctg	agtggcaggt	catacaagct	gcagttggac	atgggacttg	gccatcgctc	420
tctcttttagg	cagtccctca	cttggtaccc	agcattccca	tattccctct	ttattttgct	480
catcattcct	gctgccttag	ctcccacacc	ctactgccac	caacgttcct	ggaattttgg	540
acctagctat	ttttaaaact	gtcaactcag	gaggcacctc	cctcctcctc	tcagctgtcc	600
agtgtctggg	ccaaccatat	actctccctg	ccccctcccc	ccacaccaa	gctcctctgg	660
ctctctgacc	tcggtgagat	tgcagccagt	ccgggggatc	ggggacagac	atggagaagg	720
agatggagga	ccccctggct	ggagcagacc	aacagaatag	gcaactatgg	ctggagaacc	780
gggtatcaga	ctaagtcttg	acctcgggaa	acagtaagtc	tagatgaaat	ggcggttgct	840
ttgataagct	tttgggtcga	ggctagaatt	tcataaagtt	acagacatct	gttctgaaaa	900
ctaagatctc	tccttaccag	ataccccaat	cttcactttt	ggaccgcctg	ctcatacact	960
tattccaaaag	aagggttttg	acaggagaaa	gggagacaga	cccctcccaa	tatctgttcc	1020

<210> 21
 <211> 1120
 <212> DNA
 <213> Rattus rattus

<400> 21						
tctggcccca	cttctctgtg	gatcggtcac	cttcaaaacc	agttcagctt	cccactgccc	60
ccaccacccc	cgaaaccggg	aagcttctgt	tttttgtgtt	tgtattgacg	aggaggagg	120
attggtgcac	acactagcgt	aatggaaaag	gtggagatag	aatagacagc	tgcagagatc	180
tgatccggac	agacagaata	aaccctcctc	cgaaacaatt	ctgctctcgg	gtttcttctc	240
cagacagctg	gcctttcggc	ttctgaaata	gttggcggag	atgggggagg	gtctctgaac	300
tacgcctgcc	atccatcttc	aaagccagct	acctctacgt	accatgtgtg	gaaactcagt	360
ggcatcctca	gtaaagagag	gatgagaacg	gtgagtgaca	ggcgtcacac	aaatcaccac	420
cagccgtctt	acaggccggg	agctcattac	tgagaacgct	aaaggacctg	agtggcaggt	480
catacaagct	gcagttggac	atgggacttg	gccatcgctc	tctcttttagg	cagtccctca	540
cttggtaccc	agcattccca	tattccctct	ttattttgct	catcattcct	gctgccttag	600
ctcccacacc	ctactgccac	caacgttcct	ggaattttgg	acctagctat	ttttaaaact	660
gtcaactcag	gaggcacctc	cctcctcctc	tcagctgtcc	agtgtctggg	ccaaccatat	720
actctccttg	ccccctcccc	ccacaccaa	gctcctctgg	ctctctgacc	tcggtgagat	780
tgcagccagt	ccgggggatc	ggggacagac	atggagaagg	agatggagga	ccccctggct	840
ggagcagacc	aacagaatag	gcaactatgg	ctggagaacc	gggtatcaga	gtaatgcttg	900
acctcgggaa	acagtaagtc	tagatgaaat	ttgataagct	tttgggtcga		960
ggctagaatt	tcataaagtt	acagacatct	gttctgaaaa	ctaagatctc	tccttaccag	1020
ataccccaat	cttcactttt	ggaccgcctg	ctcatacact	tattccaaaag	aagggttttg	1080
acaggagaaa	gggagacaga	cccctcccaa	tatctgttcc			1120

<210> 22
 <211> 7265
 <212> DNA
 <213> Homo sapiens

<400> 22
 tctatataga tattaataaa tctagagaga cagaaagcag actggtgatg gccagtctag 60
 atggctagat agatagacat ggatatagat atagatctct atatagatag aggtagatac 120
 agatatagat atatgcccta ttagttctgt tcctctagag aaccttaata cagtgaccgt 180
 atttggaatc ggtccttctg ttaatttcac ttggcaagta ctaaaagatg atgatctcag 240
 atatacctat ggctgcaaaa acatgacatg gctaaatccc ttggttgag tatctctttt 300
 cttttttaag gggggtgggg gggcggtct cactgttgcc caggctggag tgcaatggcg 360
 ttatcatagc tcaatgcagc ctcaactcc tgcgtcaag tgacctcct gcctcagctc 420
 ccaaagtgtc gagattttgc aatatttatg gtcacaagat tatgttattc cataaaagta 480
 tctttctgag gctaggcatg ttggttcaca cttgtaatcc cagcactctg agaggctgag 540
 atggaaggat tcattgaggc aaggagtcca agaccagcct ggtcaacata gtgagacctc 600
 atctcggaag gaaggaagga aggagggagg gaggaaggga gggagtgaag gaaggaagga 660
 aggaaggaag gaaggaagga aggaaggaag gaaggaagga aaagtatatt tttgaatctt 720
 tttctatttc tccaactctt tctttagaag aattctattt ccattctttc ttcacctctt 780
 tgcctttgtt agccttctct ccaagcaaat cgggagcctt tattttttgt gtattcatga 840
 gggagaggaa gatgaattgc tgtacaaact aaagtaatga aaatggagta ggtaggagga 900
 tagacagctg caaggatctg agctggatag actgaacaaa cctcatcct aagcaactca 960
 cagctcagat ttcttctctg gacagctggc tttttctgct cttctgaaat actctgcaaa 1020
 gataggagag gggctatgaa ctacctctgc tatggatctt attcaaagtc agctacctcc 1080
 tagatactat ctgtagaacc taaatgtaat attcagcata gcagggatga acatggtaaa 1140
 tgaaaggat ccaattgccc actgtaattt ttaaaggcca ggagctcaac attattgaaa 1200
 atgctggagg gctgcctgga gtaggcagtg accacagagt cacacaagct ggaattggat 1260
 atccaacttg tctctcctc cctccctgac ttggcactca atactccata 1320
 ttctttctaa tctctaaacc ctcccaactc cccaactcc cacaccctac cccaccaaac 1380
 gttcctggaa ttttggaactt agctattttt aaaaccgtca actcagtagc cacctccctc 1440
 cctgctcagc tgtccagtac tctggccagc catatactcc ccttcccccc cataccaaac 1500
 cttctctggt tccctgacct cagtgaagca gcagccggcc tggggacctg ggggagacac 1560
 ggaggagccc ctggctggag ctgaccacac gagtaggaa tcatggctgg agaattggat 1620
 agcagagtaa tgtttgacct ctggaaacag taagtcaaaa tgaaattgca attcctttta 1680
 taagctttta tattgaagtt agacttttat aaaattacaa acacctactt ggatgtctct 1740
 cgtccaaatg ctgggatctc tccctaccaa ggtgccccaa tctccatttc tctttctgtc 1800
 ttatttcttt ctggcctctg gcctctagct ttttgaagtt taattctctg tctctcctct 1860
 ggcagtotta gccctctctt taccttatta cctcaagact cctgatgaag ttttagaagg 1920
 agttccctac gtcctctatt ctgtagtttt cttaccaagg ccaaataatga cctcagatga 1980
 tgagtcaactg atacccttct atcctgcccc cacttagcaa tgcccttcac attgagattc 2040
 caagcatggg ggctgtctcc tgtaaatgat ttctccccc aactctagtc cctccattct 2100
 attctccctc ttgcaggact ctcccccaa tcatatcctt acccataaga taggggagtt 2160
 aggcaggagg gatttagccc ctctccaaact cctgtcatca taaaagactg agaacttcag 2220
 aatttgaaaa gaagagatta atggaaggag tgatatttgg gaaaatacaa gaactgttga 2280
 cttagaaaaa acaaattattg atttgcatgt ttggtttgca tccattattt ccatgagaga 2340
 gggagattaa aattgcagct ctctagagct gatgaaaaga gattggtttc cttttcattt 2400
 gaatactgat attctagacg ggatgggtat gccaccctta atccttcttg tgttctgaca 2460
 caaaggagga aaagaaatgt atgactccta gagggcatct cctcctaatt gagagggaca 2520
 aataagaagt atgtttctga aatattttca ggtcctaatt ttactagggt acccactagg 2580
 attactggta tctgatctag ccccatgatt cctccatctt tgacatacct gctgtttggg 2640
 agctcagaat agtggaactc gccccttga gttcactcaa ccttccctcc 2700
 acccccacct aggggtattg cacaagggcc ctaaaagtgg ccacaggaac agggcaagga 2760
 ggcttaactg ccacacttat agtttgagga actccaatct ccccaaatc cagtctgttc 2820
 atccttttct tgatctcccc agattcactc cacattatcc ttaccaatct tcaattcttc 2880

tctctctcca	tgtccagcca	aattttctttt	ttcagtcact	tacagggcctt	ccggtcaaaa	2940
ttcactaggt	aggaggggtca	tcagctggga	agaaccggcg	cctgggaaac	ctgggtggat	3000
aggatatggg	gagccaggcc	agtcacctag	tcccaggtec	tcccatggca	gtcccccac	3060
tctaagcact	ctcactctcc	tgctgctcct	ctgtggacat	ggtaaggaa	ggccagggaa	3120
gggtttgggg	aaatctagag	ggtaggctgc	tatgtagggg	tgggcatgtg	agcctgaatg	3180
agttagggaga	gatagcgct	gagagtccc	atcactcgcc	ctgctctcaa	atactaata	3240
tttatttccc	gttcagtctg	gggaaggcca	ctggggaagc	ccttggtcga	caggcagaag	3300
agatgtggca	ggcttacaca	cttttágtaa	gacagccgag	agaactaggg	actagggggg	3360
tgggggctgg	ggaaggccct	tagttagggt	ttaggaaggc	tggaaacccc	tgatgagatt	3420
tggaaagatt	atgagcaaac	tacactccga	tagagcagag	gtctgaggac	cgtctcaca	3480
tcctctccct	tctgtcttta	gctcattctc	aatgcaagat	cctccgctgc	aatgctgagt	3540
acgtatcgtc	cactctgagc	cttagagggt	ggggttcatc	aggagcactt	cgaggaggag	3600
gaggaggagg	ccgggggtgga	gggggtgggt	ctggcgccct	ctgtcgagcc	ctccgctcct	3660
atgcgctctg	cactcgccgc	accgcccgc	cctgccgcgg	ggacctcgcc	ttccattcgg	3720
cggtacatgg	catcgaagac	ctgatgatcc	agcacaactg	ctcccgccag	ggccctacag	3780
ccccctcccc	gccccggggc	cccgcccttc	caggcgccgg	ctccggcctc	cctgccccgg	3840
acccttggtga	ctatgaaggc	cggttttccc	ggctgcattg	tcgtcccccg	gggttcttgc	3900
attgcgcttc	cttcggggac	ccccatgtgc	gcagcttcca	ccatcacttt	cacacatgcc	3960
gtgtccaagg	agcttggcct	ctactggata	atgacttctc	ctttgtccaa	gccaccagct	4020
cccccatggc	ggtggggggc	aacgctaccg	ccacccgga	ggtcaggcac	tcaatcttcc	4080
ttccgatcca	cctcatgaga	ttcttccacg	ggcaccattc	ctccccatcc	ccactattca	4140
acagcaatgc	tccttaattc	ccttttcttc	ctcaacctct	cccccatctc	gaatcactcc	4200
cttctacca	acacctggag	ctgtaaatca	cttccccctg	atgggaattt	gactcaaatg	4260
cagaaaacct	tgaagagaca	gtcggagagg	gcggaacctga	ggagtttcag	aagggaaact	4320
tttccctctc	ctaggaagtt	gccacgatta	agtagagagg	gggttaagta	gggatgaggt	4380
aatactggaa	cataaatagg	agaagggatc	aaggatttag	ggccatagta	gtcctgcatc	4440
tctacttgga	tcagatctct	aactatgtat	gaggtctgat	tggggggaag	atgcactgaa	4500
cccaaatga	actgtcttcc	ctcttgctcc	cacagctcac	catcataatt	aagaacatgc	4560
aggaatgcat	tgatcagaag	gtgtatcagg	ctgaggtgga	taatcttctc	gtagcctttg	4620
aagatggttc	tatcaatgga	ggtgaccgac	ctgggggatc	cagtttctcg	attcaaaactg	4680
ctaaccctgg	gaaccatgtg	gagatccaag	ctgcctacat	tggcacaact	ataatcattc	4740
ggcagacagc	tgggcagctc	tccttctcca	tcaaggtagc	agaggatgtg	gccatggcct	4800
tctcagctga	acaggacctg	cagctctgtg	ttgggggggt	ccctccaagt	cagcgactct	4860
ctcgatcaga	gcgcaatcgt	cggggagcta	taaccattga	tactgccaga	cggctgtgca	4920
aggaagggct	tccagtggaa	gatgcttact	tccattcctg	tgtctttgat	gttttaattt	4980
ctgggtgatcc	caactttacc	gtggcagctc	aggcagcact	ggaggatgcc	cgagccttcc	5040
tgccagactt	agagaagctg	catctcttcc	cctcagatgc	tgggggtcct	ctttcctcag	5100
caaccctctt	agctccactc	ctttctgggc	tctttgttct	gtggctttgc	attcagtaag	5160
gggaccatca	gtcccattac	tagtttgga	atgatttgga	gatacagatt	ggcatagaag	5220
aatgtaaaga	atcattaaag	gaagcagggc	ctaggagaca	cgtgaaacaa	tgacattatc	5280
cagagtcaga	tgaggctgca	gtccaggggt	gaaattatca	cagaataagg	attctgggca	5340
aggttactgc	attccggatc	tctgtggggc	tcttcacca	tttttccagc	ctcatttata	5400
gtaaacaaat	tgttctaata	catttactgc	agatttcacc	cttataagtt	tagaggtcat	5460
gaagggtttta	atgatcagta	aagatttaag	ggttgagatt	tttaagaggc	aagagctgaa	5520
agcagaagac	atgatcatta	gccataagaa	actcaaagga	ggaagacata	attagggaaa	5580
gaagtctatt	tgatgaatat	gtgtgtgtaa	ggtatgttct	gctttcttga	ttcaaaaatg	5640
aagcaggcat	tgtctagctc	ttaggtgaag	ggagtctctg	cttttgaaga	atggcacagg	5700
taggacagaa	gtatcatccc	taccccttaa	ctaactctgt	attaaagcta	caaattcttc	5760
acaccatcct	ctgttgccct	tgttgaaatc	ctttacagat	gcttgaaatg	gagtaaatgc	5820
aatgtgttca	ctccactgaa	agagggctcg	gaagtacag	atactgttgc	tatctcaggg	5880
agtttacagg	ctattggaga	gacaaaacca	attcacatga	aagagtgatg	agtgtgtaat	5940
tattcactaa	atcctacagt	atggtacatt	cagatgggaa	gatggtagat	ttgaactaaa	6000
gtaataagaa	taataaaaagg	taacagagaa	gatgggattt	gaagttagct	ttgaagactg	6060
ggtaagattc	aaattgttaa	cgatcttcca	ggcaatgaaa	accatctgga	gttatgcatg	6120
gattcatgat	tcagcaagga	aatgagcaaa	actcaaatgc	agtagacaag	gagtaatggg	6180
acagaaggtt	agatgggcag	aggccagatt	atgaagcacc	ttaaaaaggg	ggtaaggggt	6240

```

ttaaatttga ttaatatcta acacttattg aaacttaaaa tctgccaggc aatgtttttaa 6300
acacttttaa aacattgact taattctcat agctctctaa ggaagggtgtt attcttatct 6360
ctatttttat ataaggaaac ttgcctccag tcacacagct aacaaattat ggaacttgcc 6420
tccagtcaca cagttaacaa atggcagagc cagaaactga acctatgccg tttggatccc 6480
gaaacttaac ttttaatac tatactatat tgtcaaggaa gcagagagcc attaaagatt 6540
ctgggtgtgg agctggtaaa gattctaaaa ggggagttgt ggtgggtcaat gtcaccacaa 6600
aagctactct gaggtctgggc gcggtggctg acacctgtaa tccagcactt tggtaggcca 6660
atgtgggtgg atcacttgag gccaggagtt cgagaccagc ctgggcaaca tggtaaaacc 6720
ccatctctac taaaaataca agaaatttgc caggcatgat agtccatgcc tghtaatcctg 6780
taatccaagc tactcaggag gcagaggcat gagaatcgag aattgcttga acccgggcca 6840
ggaggcagag gttgcagtga gctgagacca cgccactgca ctccagcctg ggcaacagag 6900
tgagactatc aaacaaaaaa caactactct cttctcatat tctcatataa agccaaaaag 6960
agagagttgg aaaaggaggg aaagcccaaa gttgaaggaa tctagtttgt agaagaaaga 7020
ctgagaagaa atgctgttct agatgagggt gctctaaagt aacaatgctg ctctgaacaa 7080
aattatgaag gaggttaactt ttacatttaa tatcttccct gtttctggtc tcatcctccc 7140
ctctcaggta ctccataacc gaggacctgt cctccctgcc ctaatcaagt actcaccatt 7200
atcttccacc tctcctctca gtccttgaca cccgacaata ctcccctgaa caaatattac 7260
agtag

```

<210> 23
 <211> 450
 <212> PRT
 <213> Homo sapiens

```

<400> 23
Met Gln Pro Pro Arg Glu Arg Leu Val Val Thr Gly Arg Ala Gly Trp
1          5          10          15

Met Gly Met Gly Arg Gly Ala Gly Arg Ser Ala Leu Gly Phe Trp Pro
20          25          30

Thr Leu Ala Phe Leu Leu Cys Ser Phe Pro Ala Ala Thr Ser Pro Cys
35          40          45

Lys Ile Leu Lys Cys Asn Ser Glu Phe Trp Ser Ala Thr Ser Gly Ser
50          55          60

His Ala Pro Ala Ser Asp Asp Thr Pro Glu Phe Cys Ala Ala Leu Arg
65          70          75          80

Ser Tyr Ala Leu Cys Thr Arg Arg Thr Ala Arg Thr Cys Arg Gly Asp
85          90          95

Leu Ala Tyr His Ser Ala Val His Gly Ile Glu Asp Leu Met Ser Gln
100         105         110

His Asn Cys Ser Lys Asp Gly Pro Thr Ser Gln Pro Arg Leu Arg Thr
115         120         125

Leu Pro Pro Ala Gly Asp Ser Gln Glu Arg Ser Asp Ser Pro Glu Ile
130         135         140

Cys His Tyr Glu Lys Ser Phe His Lys His Ser Ala Thr Pro Asn Tyr
145         150         155         160

```

Thr His Cys Gly Leu Phe Gly Asp Pro His Leu Arg Thr Phe Thr Asp
 165 170 175
 Arg Phe Gln Thr Cys Lys Val Gln Gly Ala Trp Pro Leu Ile Asp Asn
 180 185 190
 Asn Tyr Leu Asn Val Gln Ala Thr Asn Thr Pro Val Leu Pro Gly Ser
 195 200 205
 Ala Ala Thr Ala Thr Ser Lys Leu Thr Ile Ile Phe Lys Asn Phe Gln
 210 215 220
 Glu Cys Val Asp Gln Lys Val Tyr Gln Ala Glu Met Asp Glu Leu Pro
 225 230 235 240
 Ala Ala Phe Val Asp Gly Ser Lys Asn Gly Gly Asp Lys His Gly Ala
 245 250 255
 Asn Ser Leu Lys Ile Thr Glu Lys Val Ser Gly Gln His Val Glu Ile
 260 265 270
 Gln Ala Lys Tyr Ile Gly Thr Thr Ile Val Val Arg Gln Val Gly Arg
 275 280 285
 Tyr Leu Thr Phe Ala Val Arg Met Pro Glu Glu Val Val Asn Ala Val
 290 295 300
 Glu Asp Trp Asp Ser Gln Gly Leu Tyr Leu Cys Leu Arg Gly Cys Pro
 305 310 315 320
 Leu Asn Gln Gln Ile Asp Phe Gln Ala Phe His Thr Asn Ala Glu Gly
 325 330 335
 Thr Gly Ala Arg Arg Leu Ala Ala Ala Ser Pro Ala Pro Thr Ala Pro
 340 345 350
 Glu Thr Phe Pro Tyr Glu Thr Ala Val Ala Lys Cys Lys Glu Lys Leu
 355 360 365
 Pro Val Glu Asp Leu Tyr Tyr Gln Ala Cys Val Phe Asp Leu Leu Thr
 370 375 380
 Thr Gly Asp Val Asn Phe Thr Leu Ala Ala Tyr Tyr Ala Leu Glu Asp
 385 390 395 400
 Val Lys Met Leu His Ser Asn Lys Asp Lys Leu His Leu Tyr Glu Arg
 405 410 415
 Thr Arg Asp Leu Pro Gly Arg Ala Ala Ala Gly Leu Pro Leu Ala Pro
 420 425 430
 Arg Pro Leu Leu Gly Ala Leu Val Pro Leu Leu Ala Leu Leu Pro Val
 435 440 445
 Phe Cys
 450

<210> 24
 <211> 478
 <212> PRT
 <213> Homo sapiens

<400> 24
 Met Ile Arg Lys Lys Arg Lys Arg Ser Ala Pro Pro Gly Pro Cys Arg
 1 5 10 15
 Ser His Gly Pro Arg Pro Ala Thr Ala Pro Ala Pro Pro Pro Ser Pro
 20 25 30
 Glu Pro Thr Arg Pro Ala Trp Thr Gly Met Gly Leu Arg Ala Ala Pro
 35 40 45
 Ser Ser Ala Ala Ala Ala Ala Glu Val Glu Gln Arg Arg Ser Pro
 50 55 60
 Gly Leu Cys Pro Pro Pro Leu Glu Leu Leu Leu Leu Leu Phe Ser
 65 70 75 80
 Leu Gly Leu Leu His Ala Gly Asp Cys Gln Gln Pro Ala Gln Cys Arg
 85 90 95
 Ile Gln Lys Cys Thr Thr Asp Phe Val Ser Leu Thr Ser His Leu Asn
 100 105 110
 Ser Ala Val Asp Gly Phe Asp Ser Glu Phe Cys Lys Ala Leu Arg Ala
 115 120 125
 Tyr Ala Gly Cys Thr Gln Arg Thr Ser Lys Ala Cys Arg Gly Asn Leu
 130 135 140
 Val Tyr His Ser Ala Val Leu Gly Ile Ser Asp Leu Met Ser Gln Arg
 145 150 155 160
 Asn Cys Ser Lys Asp Gly Pro Thr Ser Ser Thr Asn Pro Glu Val Thr
 165 170 175
 His Asp Pro Cys Asn Tyr His Ser His Ala Gly Ala Arg Glu His Arg
 180 185 190
 Arg Gly Asp Gln Asn Pro Pro Ser Tyr Leu Phe Cys Gly Leu Phe Gly
 195 200 205
 Asp Pro His Leu Arg Thr Phe Lys Asp Asn Phe Gln Thr Cys Lys Val
 210 215 220
 Glu Gly Ala Trp Pro Leu Ile Asp Asn Asn Tyr Leu Ser Val Gln Val
 225 230 235 240
 Thr Asn Val Pro Val Val Pro Gly Ser Ser Ala Thr Ala Thr Asn Lys
 245 250 255
 Ile Thr Ile Ile Phe Lys Ala His His Glu Cys Thr Asp Gln Lys Val

17

260	265	270
Tyr Gln Ala Val Thr Asp Asp Leu Pro Ala Ala Phe Val Asp Gly Thr		
275	280	285
Thr Ser Gly Gly Asp Ser Asp Ala Lys Ser Leu Arg Ile Val Glu Arg		
290	295	300
Glu Ser Gly His Tyr Val Glu Met His Ala Arg Tyr Ile Gly Thr Thr		
305	310	315
Val Phe Val Arg Gln Val Gly Arg Tyr Leu Thr Leu Ala Ile Arg Met		
325	330	335
Pro Glu Asp Leu Ala Met Ser Tyr Glu Glu Ser Gln Asp Leu Gln Leu		
340	345	350
Cys Val Asn Gly Cys Pro Leu Ser Glu Arg Ile Asp Asp Gly Gln Gly		
355	360	365
Gln Val Ser Ala Ile Leu Gly His Ser Leu Pro Arg Thr Ser Leu Val		
370	375	380
Gln Ala Trp Pro Gly Tyr Thr Leu Glu Thr Ala Asn Thr Gln Cys His		
385	390	395
Glu Lys Met Pro Val Lys Asp Ile Tyr Phe Gln Ser Cys Val Phe Asp		
405	410	415
Leu Leu Thr Thr Gly Asp Ala Asn Phe Thr Ala Ala Ala His Ser Ala		
420	425	430
Leu Glu Asp Val Glu Ala Leu His Pro Arg Lys Glu Arg Trp His Ile		
435	440	445
Phe Pro Ser Ser Gly Asn Gly Thr Pro Arg Gly Gly Ser Asp Leu Ser		
450	455	460
Val Ser Leu Gly Leu Thr Cys Leu Ile Leu Ile Val Phe Leu		
465	470	475

<210> 25
 <211> 420
 <212> PRT
 <213> Mus musculus

<400> 25

Met Gly Gln Ser Pro Ser Pro Arg Ser Pro His Gly Ser Pro Pro Thr
1 5 10 15
Leu Ser Thr Leu Thr Leu Leu Leu Leu Cys Gly Gln Ala His Ser
20 25 30
Gln Cys Lys Ile Leu Arg Cys Asn Ala Glu Tyr Val Ser Ser Thr Leu

18

35					40					45					
Ser	Leu	Arg	Gly	Gly	Gly	Ser	Pro	Asp	Thr	Pro	Arg	Gly	Gly	Gly	Arg
50						55					60				
Gly	Gly	Leu	Ala	Ser	Gly	Gly	Leu	Cys	Arg	Ala	Leu	Arg	Ser	Tyr	Ala
65					70					75					80
Leu	Cys	Thr	Arg	Arg	Thr	Ala	Arg	Thr	Cys	Arg	Gly	Asp	Leu	Ala	Phe
			85					90						95	
His	Ser	Ala	Val	His	Gly	Ile	Glu	Asp	Leu	Met	Ile	Gln	His	Asn	Cys
			100					105						110	
Ser	Arg	Gln	Gly	Pro	Thr	Ala	Pro	Pro	Pro	Ala	Arg	Gly	Pro	Ala	Leu
		115					120					125			
Pro	Gly	Ala	Gly	Pro	Ala	Pro	Leu	Thr	Pro	Asp	Pro	Cys	Asp	Tyr	Glu
	130					135					140				
Ala	Arg	Phe	Ser	Arg	Leu	His	Gly	Arg	Ala	Pro	Gly	Phe	Leu	His	Cys
145					150					155					160
Ala	Ser	Phe	Gly	Asp	Pro	His	Val	Arg	Ser	Phe	His	Asn	Gln	Phe	His
				165					170					175	
Thr	Cys	Arg	Val	Gln	Gly	Ala	Trp	Pro	Leu	Leu	Asp	Asn	Asp	Phe	Leu
			180					185					190		
Phe	Val	Gln	Ala	Thr	Ser	Ser	Pro	Val	Ser	Ser	Gly	Ala	Asn	Ala	Thr
		195					200					205			
Thr	Ile	Arg	Lys	Ile	Thr	Ile	Ile	Phe	Lys	Asn	Met	Gln	Glu	Cys	Ile
	210					215					220				
Asp	Gln	Lys	Val	Tyr	Gln	Ala	Glu	Val	Asp	Asn	Leu	Pro	Ala	Ala	Phe
225					230					235					240
Glu	Asp	Gly	Ser	Ile	Asn	Gly	Gly	Asp	Arg	Pro	Gly	Gly	Ser	Ser	Leu
			245						250					255	
Ser	Ile	Gln	Thr	Ala	Asn	Leu	Gly	Ser	His	Val	Glu	Ile	Arg	Ala	Ala
			260					265					270		
Tyr	Ile	Gly	Thr	Thr	Ile	Ile	Ile	Arg	Gln	Thr	Ala	Gly	Gln	Leu	Ser
		275					280					285			
Phe	Ser	Ile	Arg	Val	Ala	Glu	Asp	Val	Ala	Arg	Ala	Phe	Ser	Ala	Glu
	290					295					300				
Gln	Asp	Leu	Gln	Leu	Cys	Val	Gly	Gly	Cys	Pro	Pro	Ser	Gln	Arg	Leu
305					310					315					320
Ser	Arg	Ser	Glu	Arg	Asn	Arg	Arg	Gly	Ala	Ile	Ala	Ile	Asp	Thr	Ala
				325					330					335	

Arg Arg Leu Cys Lys Glu Gly Leu Pro Val Glu Asp Ala Tyr Phe Gln
 340 345 350
 Ser Cys Val Phe Asp Val Ser Val Ser Gly Asp Pro Asn Phe Thr Val
 355 360 365
 Ala Ala Gln Thr Ala Leu Asp Asp Ala Arg Ile Phe Leu Thr Asp Leu
 370 375 380
 Glu Asn Leu His Leu Phe Pro Ser Asp Ala Gly Pro Pro Leu Ser Pro
 385 390 395 400
 Ala Ile Cys Leu Val Pro Leu Leu Ser Ala Leu Phe Val Leu Trp Leu
 405 410 415
 Cys Phe Ser Lys
 420

<210> 26
 <211> 422
 <212> PRT
 <213> Rattus rattus

<400> 26
 Met Gly Asp Arg Gly Arg Ser Pro Ser Leu Arg Ser Pro His Gly Ser
 1 5 10 15
 Pro Pro Thr Leu Ser Thr Leu Thr Leu Leu Leu Leu Cys Gly Gln
 20 25 30
 Ala His Ser Gln Cys Lys Ile Leu Arg Cys Asn Ala Glu Tyr Val Ser
 35 40 45
 Phe Thr Leu Ser Leu Arg Gly Gly Gly Ser Pro Asp Thr Pro Arg Gly
 50 55 60
 Gly Gly Arg Gly Gly Pro Ala Ser Gly Gly Leu Cys Arg Ala Leu Arg
 65 70 75 80
 Ser Tyr Ala Leu Cys Thr Arg Arg Thr Ala Arg Thr Cys Arg Gly Asp
 85 90 95
 Leu Ala Phe His Ser Ala Val His Gly Ile Glu Asp Leu Met Ile Gln
 100 105 110
 His Asn Cys Ser Arg Gln Gly Pro Thr Ala Ser Pro Pro Ala Arg Gly
 115 120 125
 Pro Ala Leu Pro Gly Ala Gly Pro Ala Pro Leu Thr Pro Asp Pro Cys
 130 135 140
 Asp Tyr Glu Ala Arg Phe Ser Arg Leu His Gly Arg Thr Pro Gly Phe
 145 150 155 160
 Leu His Cys Ala Ser Phe Gly Asp Pro His Val Arg Ser Phe His Asn

165

170

175

<210>	27
<211>	366
<212>	PRT
<213>	Fugu

<400> 27
 Ala Ser Cys Arg Ile Leu Arg Cys Asn Ser Asp Phe Val Ala Ala Thr
 1 5 10 15
 Leu Asp Leu Gly Ser Ser Ala Gly Ala Gly Gly Gly Ala Pro Leu Ser
 20 25 30
 Arg Glu Ala Ala Asn Ala Glu Tyr Cys Arg Ala Leu His Ser Tyr Ser
 35 40 45
 Thr Cys Thr Lys Arg Met Ala Arg Pro Cys Arg Gly Asp Leu Ala Tyr
 50 55 60
 His Ser Ala Val Gln Gly Ile Glu Asp Leu Leu Ile Gln Tyr Arg Cys
 65 70 75 80
 Pro Leu Ala Gly Pro Thr Ala Gln Pro Arg Pro Leu Pro Pro Leu Leu
 85 90 95
 Ser Gly Asp Val Cys Leu Tyr Asp Arg Arg Leu Ala Ala Ala Glu Ala
 100 105 110
 Pro Gln Pro Asp Tyr Leu His Cys Gly Val Phe Gly Asp Pro His Ile
 115 120 125
 Arg Thr Phe Asn Asn Asp Phe His Thr Cys Ala Val Gln Gly Ala Trp
 130 135 140
 Pro Leu Ile Asp Asn Asp Phe Leu Tyr Val Gln Ala Thr Ser Ser Pro
 145 150 155 160
 Thr Arg Arg Gly Thr Gln Ala Thr Met Leu Thr Lys Ile Thr Val Ile
 165 170 175
 Val Lys Ser Trp Arg His Cys Val Asp Gln Gln Leu Tyr Gln Ala Glu
 180 185 190
 Leu Asp Asp Val Pro Met Ala Phe Ala Asp Gly Ser Val Val Ser Gly
 195 200 205
 Glu Arg Arg Gly Gln His Thr Leu Ala Ile Thr Gln Ser Pro Gly Arg
 210 215 220
 His Ala Glu Ile Arg Ala Ala His Ile Ala Thr Val Ala Ser Gly Gln
 225 230 235 240
 Ser Gly Arg Ser Leu Ser Leu Ser Val Tyr Ser Pro Arg Ser Val Val
 245 250 255
 Glu Ala Phe Gly Pro Glu Gln Asp Leu Gln Leu Cys Met Trp Gly Cys
 260 265 270
 Pro Ala Ser Gln Lys Leu Ser Thr Pro Pro Pro Thr Ser Ser Thr Phe
 275 280 285
 Ser Ala Ala Val Leu Ala His Cys Asp Ala Leu Leu Pro Val Arg Asp

290 295 300
 Val Tyr His Gln Ala Cys Ile Phe Asp Leu Ile Thr Ser Gly Asp Leu
 305 310 315 320
 Asn Ser Ser Gly Ala Ala Ile Ser Ala Leu Gln Asp Ala Gln Lys Leu
 325 330 335
 Ile Ser Asp Pro Lys Arg Val His Leu Leu Ser Pro Thr Ser Ala Ala
 340 345 350
 Gln Arg Glu Asp His Leu Cys Leu Leu Leu Leu Leu Ser
 355 360 365

 <210> 28
 <211> 432
 <212> PRT
 <213> Chicken

 <400> 28
 Met Gly Arg Gly Ala Gly Ser Thr Ala Leu Gly Leu Phe Gln Ile Leu
 1 5 10 15
 Pro Val Phe Leu Cys Ile Phe Pro Pro Val Thr Ser Pro Cys Lys Ile
 20 25 30
 Leu Lys Cys Asn Ser Glu Phe Trp Ala Ala Thr Ser Gly Ser His His
 35 40 45
 Leu Gly Ala Glu Glu Thr Pro Glu Phe Cys Thr Ala Leu Arg Ala Tyr
 50 55 60
 Ala His Cys Thr Arg Arg Thr Ala Arg Thr Cys Arg Gly Asp Leu Ala
 65 70 75 80
 Tyr His Ser Ala Val His Gly Ile Asp Asp Leu Met Val Gln His Asn
 85 90 95
 Cys Ser Lys Asp Gly Pro Thr Ser Gln Pro Arg Leu Arg Thr Leu Pro
 100 105 110
 Pro Gly Asp Ser Gln Glu Arg Ser Asp Ser Pro Glu Ile Cys His Tyr
 115 120 125
 Glu Lys Ser Phe His Lys His Ser Ala Ala Pro Asn Tyr Thr His Cys
 130 135 140
 Gly Leu Phe Gly Asp Pro His Leu Arg Thr Phe Thr Asp Thr Phe Gln
 145 150 155 160
 Thr Cys Lys Val Gln Gly Ala Trp Pro Leu Ile Asp Asn Asn Tyr Leu
 165 170 175
 Asn Val Gln Val Thr Asn Thr Pro Val Leu Pro Gly Ser Ser Ala Thr

23

180										185										190										
Ala	Thr	Ser	Lys	Leu	Thr	Ile	Ile	Phe	Lys	Ser	Phe	Gln	Glu	Cys	Val															
			195				200					205																		
Glu	Gln	Lys	Val	Tyr	Gln	Ala	Glu	Met	Asp	Glu	Leu	Pro	Ala	Ala	Phe															
	210					215					220																			
Ala	Asp	Gly	Ser	Lys	Asn	Gly	Gly	Asp	Lys	His	Gly	Ala	Asn	Ser	Leu															
	225				230					235					240															
Lys	Ile	Thr	Glu	Lys	Val	Ser	Gly	Gln	His	Ile	Glu	Ile	Gln	Ala	Lys															
				245					250						255															
Tyr	Ile	Gly	Thr	Thr	Ile	Val	Val	Arg	Gln	Val	Gly	Arg	Tyr	Leu	Thr															
			260					265					270																	
Phe	Ala	Val	Arg	Met	Pro	Glu	Glu	Val	Val	Asn	Ala	Val	Glu	Asp	Arg															
		275					280					285																		
Asp	Ser	Gln	Gly	Leu	Tyr	Leu	Cys	Leu	Arg	Gly	Cys	Pro	Leu	Asn	Gln															
	290					295					300																			
Gln	Ile	Asp	Phe	Gln	Thr	Phe	Arg	Leu	Ala	Gln	Ala	Ala	Glu	Gly	Arg															
	305				310					315					320															
Ala	Arg	Arg	Lys	Gly	Pro	Ser	Leu	Pro	Ala	Pro	Pro	Glu	Ala	Phe	Thr															
			325						330					335																
Tyr	Glu	Ser	Ala	Thr	Ala	Lys	Cys	Arg	Glu	Lys	Leu	Pro	Val	Glu	Asp															
		340					345						350																	
Leu	Tyr	Phe	Gln	Ser	Cys	Val	Phe	Asp	Leu	Leu	Thr	Thr	Gly	Asp	Val															
	355						360						365																	
Asn	Phe	Met	Leu	Ala	Ala	Tyr	Tyr	Ala	Phe	Glu	Asp	Val	Lys	Met	Leu															
	370					375					380																			
His	Ser	Asn	Lys	Asp	Lys	Leu	His	Leu	Tyr	Glu	Arg	Thr	Arg	Ala	Leu															
	385				390					395					400															
Ala	Pro	Gly	Asn	Ala	Ala	Pro	Ser	Glu	His	Pro	Trp	Ala	Leu	Pro	Ala															
			405					410					415																	
Leu	Trp	Val	Ala	Leu	Leu	Ser	Leu	Ser	Gln	Cys	Trp	Leu	Gly	Leu	Leu															
		420					425						430																	

<210> 29

<211> 21

<212> DNA

<213> Artificial

<220>

<223> Polynucleotide replication primer

24

<400> 29
tccaagtcag cgactctctc g 21

<210> 30
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Polynucleotide replication primer

<400> 30
tccaagtcag tgactctctc g 21

<210> 31
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 31
acctgccgcg gggacctcgc c 21

<210> 32
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 32
acctgccgcg tggacctcgc c 21

<210> 33
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 33
gcctgggaaa cctggctgga t 21

<210> 34
<211> 21
<212> DNA
<213> Artificial

25

<220>

<223> Fragment containing polymorphism

<400> 34

gcctgggaaa gctgggtgga t

21

<210> 35

<211> 21

<212> DNA

<213> Artificial

<220>

<223> Fragment containing polymorphism

<400> 35

tcccttctgt ctttagctca t

21

<210> 36

<211> 21

<212> DNA

<213> Artificial

<220>

<223> Fragment containing polymorphism

<400> 36

tcccttctgt gtttagctca t

21

<210> 37

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Fragment containing polymorphism

<400> 37

gaggaggagg ccggggtgga

20

<210> 38

<211> 23

<212> DNA

<213> Artificial

<220>

<223> Fragment containing polymorphism

<400> 38

gaggaggagg aggccggggt gga

23

26

<210> 39
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 39
gcctccctgc cccggaccct t

21

<210> 40
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 40
gcctccctgc gccggaccct t

21

<210> 41
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 41
atggtcgtcc cccgggggttc t

21

<210> 42
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 42
atggtcgtcc accgggggttc t

21

<210> 43
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 43
cgtcccccg ggttcttgca t 21

<210> 44
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 44
cgtcccccg cgttcttgca t 21

<210> 45
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 45
gtccaaggag cttggcctct a 21

<210> 46
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 46
gtccaaggag attggcctct a 21

<210> 47
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 47
cccccatggc gttgggggcc a 21

<210> 48
<211> 21
<212> DNA
<213> Artificial

28

<220>
<223> Fragment containing polymorphism

<400> 48
cccccatggc tttgggggcc a 21

<210> 49
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 49
taagaacatg caggaatgca t 21

<210> 50
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 50
taagaacatg aaggaatgca t 21

<210> 51
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 51
gccttctcag ctgaacagga c 21

<210> 52
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Fragment containing polymorphism

<400> 52
gccttctcag gtgaacagga c 21

<210> 53
<211> 21

29

<212> DNA
<213> Artificial
<220>
<223> Fragment containing polymorphism
<400> 53
agatgctggg gttcctcttt c 21

<210> 54
<211> 21
<212> DNA
<213> Artificial
<220>
<223> Fragment containing polymorphism
<400> 54
agatgctggg attcctcttt c 21

<210> 55
<211> 20
<212> DNA
<213> Artificial
<220>
<223> Forward replication primer
<400> 55
cacttgagcc caggaatttg 20

<210> 56
<211> 20
<212> DNA
<213> Artificial
<220>
<223> Reverse replication primer
<400> 56
gactcactgc agccttgacc 20

<210> 57
<211> 22
<212> DNA
<213> Artificial
<220>
<223> Forward replication primer
<400> 57
gtgtgctaca agtttgccga at 22

<210> 58
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Reverse replication primer

<400> 58
gcttgaaact gggagttgga

20

<210> 59
<211> 22
<212> DNA
<213> Artificial

<220>
<223> Forward replication primer

<400> 59
gggaaatggt cccataattc ct

22

<210> 60
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Reverse replication primer

<400> 60
cgccctgccca atatgttct

19

<210> 61
<211> 22
<212> DNA
<213> Artificial

<220>
<223> Forward replication primer

<400> 61
ggtacttagc ctcgaaatga ga

22

<210> 62
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Reverse replication primer

<400> 62
gtgtcacaca actggttggt

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT.

☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**